



Coverage Policy

Effective Date 3/15/2025
Next Review Date 3/15/2026
Coverage Policy Number EN0383

Transcranial Magnetic Stimulation

Table of Contents

Overview	1
Coverage Policy	2
Health Equity Considerations	3
General Background	4
Medicare Coverage Determinations	25
Coding Information	25
References	26
Revision Details	48

Related Coverage Resources

[Attention-Deficit/Hyperactivity Disorder \(ADHD\): Assessment and Treatment](#)
[Complementary and Alternative Medicine](#)
[Deep Brain, Motor Cortex and Responsive Cortical Stimulation](#)
[Electrical Stimulation Therapy and Home Devices](#)
[Vagus Nerve Stimulation \(VNS\)](#)

INSTRUCTIONS FOR USE

Coverage Policies are intended to provide guidance in interpreting benefit plans administered by Cigna Companies. Please note, the terms of a customer's particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer's benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a customer's benefit plan document always supersedes the information in the Coverage Policies. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of 1) the terms of the applicable benefit plan document in effect on the date of service; 2) any applicable laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular situation. Each coverage request should be reviewed on its own merits. Medical directors are expected to exercise clinical judgment where appropriate and have discretion in making individual coverage determinations. Where coverage for care or services does not depend on specific circumstances, reimbursement will only be provided if a requested service(s) is submitted in accordance with the relevant criteria outlined in the applicable Coverage Policy, including covered diagnosis and/or procedure code(s). Reimbursement is not allowed for services when billed for conditions or diagnoses that are not covered under this Coverage Policy (see "Coding Information" below). When billing, providers must use the most appropriate codes as of the effective date of the submission. Claims submitted for services that are not accompanied by covered code(s) under the applicable Coverage Policy will be denied as not covered. Coverage Policies relate exclusively to the administration of health benefit plans. Coverage Policies are not recommendations for treatment and should never be used as treatment guidelines.

Overview

This Coverage Policy addresses the various types of transcranial magnetic stimulation (TMS) for the treatment of unipolar major depressive disorder, obsessive-compulsive disorder, and other psychiatric and neurological conditions in the adult and adolescent populations.

Coverage Policy

Initial Transcranial Magnetic Stimulation (TMS) for Treatment of Major Depressive Disorder

An initial regimen (i.e. 30-36 treatments) of transcranial magnetic stimulation administered in an outpatient office setting using a U.S. Food and Drug Administration (FDA) approved device is considered medically necessary for major depressive disorder when an individual meets ALL of the following criteria:

- age 15 years or older
- diagnosis of major depressive disorder (unipolar), moderate-to-severe, single or recurrent episode or acute relapse, without psychosis, as defined by the most recent edition of Diagnostic and Statistical Manual of Mental Disorders
- during the current episode of depression **ALL** of the following criteria are met:
 - an adequate trial of an evidence-based psychotherapy known to be effective in the treatment of major depressive disorder, without significant improvement in depressive symptoms
 - validated depression monitoring scales are administered at the beginning and at the end of the initial and each subsequent course of TMS
 - failure of an antidepressant medication trial* for **EITHER** of the following populations:
 - for an adult age 18 years or older: failure of two or more trials of antidepressant medications from two separate classes of antidepressant medications
 - for an adolescent age 15–17: failure of two trials of antidepressant medications

***NOTE:** A failed antidepressant medication trial is defined as **EITHER** of the following:

- use of an antidepressant medication at adequate therapeutic doses for at least four weeks with no significant reduction in depressive symptoms
- use of an antidepressant medication with documented intolerance or medical contraindication

Repeat TMS for Treatment of Major Depressive Disorder

Repeat transcranial magnetic stimulation (TMS) (i.e. 30-36 treatments) administered in an outpatient office setting for a recurrence or an acute relapse of major depressive disorder is considered medically necessary when ALL of the following criteria are met:

- individual had more than a 50% improvement as evidenced by one or more standard rating scales for depression at the end of the most recent course of TMS
- improvement has been maintained for at least two months after the most recent course of TMS

Initial TMS for Treatment of Obsessive-Compulsive Disorder

An initial regimen (i.e. 30-36 treatments) of deep transcranial magnetic stimulation (TMS) administered in an outpatient office setting using a U.S. Food and Drug Administration (FDA) approved device for obsessive-compulsive disorder (OCD) is considered medically necessary for OCD when an individual meets ALL of the following criteria:

- age 18 years or older
- diagnosis of OCD as defined by the most recent edition of Diagnostic and Statistical Manual of Mental Disorders
- failure of two or more trials of psychopharmacologic medications for the treatment of OCD. A failed trial is defined as **EITHER** of the following:
 - use of a psychopharmacologic medication at adequate therapeutic doses for at least eight weeks with no significant reduction in OCD symptoms
 - use of a psychopharmacologic medication with documented intolerance or medical contraindication
- an adequate trial of an evidence-based psychotherapy known to be effective in the treatment of OCD, without significant improvement in OCD symptoms
- the Yale-Brown Obsessive Compulsive Scale (Y-BOCS) is administered at the beginning and at the end of the initial and each subsequent course of TMS

Repeat TMS for Treatment of Obsessive-Compulsive Disorder

Repeat deep transcranial magnetic stimulation (TMS) (i.e. 30-36 treatments) administered in an outpatient office setting for a recurrence or an acute relapse of OCD is considered medically necessary when ALL of the following criteria are met:

- individual had more than a 30% improvement as evidenced by Yale-Brown Obsessive Compulsive Scale (Y-BOCS) at the end of the most recent course of TMS
- improvement has been maintained for at least two months after initial course of TMS

Not Medically Necessary

Transcranial magnetic stimulation (TMS), used as a maintenance therapy, is considered not medically necessary.

Transcranial magnetic stimulation (TMS) for any other indication, including but not limited to migraine headaches, is considered not medically necessary.

Experimental, Investigational or Unproven

Accelerated treatment protocols (e.g., Theta Burst Stimulation (TBS), Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT), Stanford Neuromodulation Therapy (SNT)), are considered experimental, investigational or unproven.

Health Equity Considerations

Health equity is the highest level of health for all people; health inequity is the avoidable difference in health status or distribution of health resources due to the social conditions in which people are born, grow, live, work, and age.

Social determinants of health are the conditions in the environment that affect a wide range of health, functioning, and quality of life outcomes and risks. Examples include safe housing, transportation and neighborhoods; racism, discrimination and violence; education, job opportunities and income; access to nutritious foods and physical activity opportunities; access to clean air and water; and language and literacy skills.

The American Psychiatric Association (APA) stated in a 2019 clinical practice guideline for the treatment of depression, that major depression was the third leading cause of worldwide disability in 1990 and had risen to the second cause by 2013 both worldwide and in the United States. Due to direct effects associated with increased risk of suicide, reduced functional behaviors, and

interpersonal functioning, major depression leads to increased morbidity and mortality and reduced work productivity. Approximately 6.7–7.6% of adults reported an episode of major depression in a 12-month period with women having approximately 1.7 times the risk as men. Lifetime prevalence is estimated at 17.9% and major depression frequently occurs with comorbid mental health conditions such as anxiety and substance use disorders (APA, 2019).

According to a 2023 clinical practice guideline on the assessment and treatment of children and adolescents with major and persistent depressive disorders, the American Academy of Child and Adolescent Psychiatry (AACAP) stated that nearly 3% of youth worldwide were reported to have a depressive disorder. In the United States, the lifetime prevalence of MDD in adolescents was reported to be 11% with markedly greater increases in prevalence among female individuals compared to male. The past year prevalence of MDD in a nationally representative sample of adolescents increased from 8.7%–11.3% from 2005–2014. Some form of suicidality in the past year was reported by 30% of youth with MDD and more than 10% reported a suicide attempt. Disorder-specific treatment was reported in 34% of adolescents with MDD. Compared to adults, MDD in adolescents more commonly presents with sad mood, neurovegetative symptoms, and suicidality. Recurrence rates in adolescents is estimated to be 20–60% in one to two years and 70% after five years. The AACAP reported that the onset of MDD in youth has been characterized by exposure to adverse childhood circumstances (e.g., interpersonal loss, parental maladjustment, child maltreatment, economic adversity) and concurrent psychiatric comorbidity (e.g., anxiety, behavior and attention disorders). Pharmacologic treatment options for this population are limited to those SSRIs that have received FDA approval for the treatment of depression in youth (i.e., fluoxetine and escitalopram) (Walter, et al., 2023).

General Background

Transcranial magnetic stimulation (TMS) is a non-invasive neurostimulation technique that modulates cortical excitability. In repetitive TMS (rTMS), trains of several pulses are delivered through repeated stimulation over the same area with frequencies ranging from 1 to 20 Hz. The two most commonly used methods of TMS are repetitive transcranial magnetic stimulation (rTMS) and deep TMS (dTMS). Standard repetitive transcranial magnetic stimulation delivers a magnetic field to a maximal depth of approximately two centimeters (cm) below the cortical surface and is also called surface cortical TMS or superficial TMS. Surface cortical rTMS of the left dorsolateral prefrontal cortex (DLPFC) is the most widely used and studied form of TMS. The site most commonly used for the treatment of depression is the left prefrontal cortex. TMS is typically applied to the skull with an electromagnetic coil called a figure-of-eight coil (8-coil) (Feffer, et al., 2017).

Deep transcranial (dTMS) stimulates brain structures beneath the superficial prefrontal cortex using a magnetic Hesel-coil (H-coil). The H-coil is proposed to cause cortical excitability up to a maximum depth of six centimeters which causes modulation of the activity of the cerebral cortex and of deeper neural circuits making it more effective than surface stimulation. H-coils stimulate a larger area of the brain than the conventional figure-8 coils. There are 14 different H-coils designed to target specific brain regions (e.g., H1, H2, H1L) based on the area and method of stimulation. In H-coil therapy, the electromagnetic coil is contained in a helmet with multiple windings in multiple planes. Although deep stimulation can also be accomplished with a large circular coil or a double cone coil, their electromagnetic field decays more rapidly and to reach significantly deep targets much higher intensities must be used on the surface. Reported side effects include headaches, facial pain, tooth pain, neck pain and seizure (Feffer, et al., 2017; Tendler, et al., 2017; Feifel, et al., 2016; Nordenskjold, et al., 2016; Tendler, et al., 2016; Bersani, et al. 2013).

The effects of TMS depend on the parameters of waveform, frequency, intensity, and duration of stimulation. Due to the lower energy requirements, a biphasic waveform is frequently used in

stimulation. Frequency is one of the most important parameters in rTMS protocols that affect the clinical outcome. High frequency (HF) rTMS usually comprises frequencies ≥ 5 Hz, while low frequency (LF) rTMS includes frequencies ≤ 1 Hz. Evidence has suggested that LF-rTMS is “inhibitory” while HF-rTMS is “excitatory” (Guo, et al., 2017). The electromagnetic current repeatedly switches on and off for up to 10 times per second to produce the pulses. To determine the therapeutic magnetic strength, the amount of magnetic energy is adjusted until the motor threshold is reached (i.e., the patient’s fingers or hands start to twitch). The pulses are proposed to induce electric currents to depolarize neurons in a focal area of the surface cortex and alter brain activity in areas responsible for mood. rTMS is less invasive than vagal nerve stimulation and is not intended to induce seizures like electroconvulsive therapy (ECT). rTMS may cause some short-term side effects such as headache, tingling of facial muscles, scalp discomfort, lightheadedness, or discomfort from the noise that the device makes. Hearing loss and seizures have been reported as uncommon side effects. Symptom relief may not take place for several weeks (Guo, et al., 2017; Allan, et al., 2011).

Transcranial Magnetic Stimulation (TMS) for Depression

Initial rTMS is a treatment option for an adult or adolescent with a diagnosis of unipolar, depressive disorder, moderate-to-severe, single or recurrent episode or acute relapse, without psychosis, as defined by the most recent edition of the Diagnostic and Statistical Manual (DSM) of Mental Disorders. Potential TMS candidates are those patients who have failed at least two trials of antidepressant medications, at adequate therapeutic doses, including, for adults, at least two different classes for a period of at least four weeks. The regimen should have included one or more anti-depressant medications. Antidepressant classes include: selective serotonin reuptake inhibitors (SSRIs; e.g., sertraline, fluoxetine), serotonin-norepinephrine reuptake inhibitors (SNRIs; e.g., desvenlafaxine, duloxetine), tricyclic antidepressants (TCAs; e.g., amitriptyline, nortriptyline, desipramine) and monoamine oxidase inhibitors (MAOIs; e.g., isocarboxazid, phenelzine), and may be given in combination regimens. Following pharmacotherapy, TMS candidates are those who demonstrate no significant reduction in depressive symptoms which is documented by results of validated depression monitoring scales (e.g., Patient Health Questionnaire [PHQ-9], Beck Depression Inventory [BDI], Hamilton Depression Rating Scale [HAM-D], Montgomery-Asberg Depression Rating Scale [MADRS], Quick Inventory of Depressive Symptomatology Self-reported [QIDS], Inventory of Depressive Symptomatology Clinician-rated [IDS-SR score]). Adherence to the medication should be documented or it should be documented if the patient has intolerance to the medication or could not take the medication due to medical contraindications (Institute for Clinical Systems Improvement [ICSI], 2016; FDA, 2018).

A major depressive episode as defined in the DSM-5 implies a prominent and relatively persistent (e.g., nearly every day for at least two weeks) depressed or dysphoric mood that represents a change from previous functioning, and includes at least five of the following nine symptoms, one of which is either of the first two symptoms (Institute for Clinical Systems Improvement [ICSI], 2016):

- Depressed mood
- Markedly diminished interest or pleasure in usual activities
- Significant change in weight and/or appetite
- Insomnia or hypersomnia
- Psychomotor agitation or retardation
- Fatigue or loss of energy
- Feelings of worthlessness or excessive or inappropriate guilt
- Slowed thinking or impaired concentration
- Recurrent thoughts of death or suicidal ideation or a suicide attempt

Standard treatments for major depressive disorder (MDD) include psychotherapy, pharmacotherapy, and/or electroconvulsive therapy (ECT). Although the majority of individuals respond to standard treatments for depression, some do not benefit, or cannot tolerate these interventions. Therefore, alternate treatment options are being investigated, including transcranial magnetic stimulation (TMS), vagal nerve stimulation, cranial electrical stimulation and herbal/homeopathic remedies (Miniussi, et al., 2005).

TMS should also be preceded by evidenced-based psychotherapy (e.g., cognitive behavioral psychotherapy, interpersonal psychotherapy, psychodynamic therapy) known to be effective for the treatment of depression. TMS candidates are those who do not show significant improvement on depression monitoring scales following psychotherapy. Adequate therapy may include at least one weekly session for at least 12 weeks. A face-to-face psychiatric evaluation that establishes that the diagnostic criteria are met for major depressive disorder should be performed and documented. An assessment of currently prescribed medications and a medical assessment to evaluate for any medical conditions that might increase the risks associated with TMS and/or the presence of contraindications to TMS are indicated. The patient should be educated regarding potential risks and benefits of the procedure. Because TMS may be associated with an increased risk of a seizure, the benefits of TMS use must be carefully considered against the risk in individuals taking medications which may lower the seizure threshold (Hayes, 2014; reviewed 2018).

Response is clinically defined as an improvement in symptoms from the initial onset of depression. The term remission has typically been applied to being symptom free or having minimal symptoms, representing an end to the immediate episode. The DSM-5 defines remission as a period of two or more months with no symptoms or only 1-2 mild symptoms. Partial remission involves significant improvement but mild symptoms of MDD are still present or there are no longer any significant symptoms of a Major Depressive Episode, but the period of remission has been less than two months. Recovery is the absence of symptoms for at least four months following the onset of remission with periods of improvement. Relapse has been defined as the re-emergence or early return of the depressive episode of full or significant depressive symptoms after remission. In their study, Jang et al. (2013) defined relapse as subjects who had HAM-D 17 score of 14 or more, and CGI-S score of three or more (with at least a 2-point increase from double-blind baseline), and meeting protocol defined DSM-IV criteria for MDD. Recurrence refers to a subsequent, new depressive episode after full recovery has been achieved. (PsychCentral, 2022; Gili, et al., 2015; APA, 2010; Dobson, et al., 2008; Paykel et al., 2008).

The initial course of TMS typically includes 30–36 total treatments, with one treatment per day, over a 4–6-week period. Six tapered treatments over the final three-week period may be included in the total 30-36 visits (Hutton, et al., 2023). A typical course of TMS does not include concurrent or overlapping courses of TMS for either Major Depressive Disorder (MDD) or Obsessive-Compulsive Disorder (OCD). Treatment will last for 30–60 minutes, and the entire session may take up to two hours. TMS is administered in an outpatient setting by a Board-certified or Board-eligible physician or advanced practice psychiatric nurse practitioner (within the scope of their license) who has completed specialized training for TMS administration. The procedure does not require anesthesia.

A history of a favorable response to TMS in a previous episode of depression with more than a 50% improvement is predictive of a favorable clinical outcome (Hayes, 2014, reviewed 2018; FDA, 2018; O'Reardon, et al., 2007). Repeat treatments may be appropriate for acute relapse or recurrence when the patient experienced more than a 50% improvement in the initial TMS regimen as noted by standard rating scales used to measure depressive symptoms (e.g. Patient Health Questionnaire [PHQ-9], Beck Depression Inventory [BDI], Hamilton Depression Rating Scale [HAM-D], Montgomery-Asberg Depression Rating Scale [MADRS], Quick Inventory of Depressive Symptomatology Self-reported [QIDS], Inventory of Depressive Symptomatology

Clinician-rated [IDS-SR score]) (Fitzgerald, et al., 2013; Mantovan, et al., 2012a; Jacicak, et al., 2010).

Maintenance TMS has been proposed, but maintenance regimens have not been established, and reported outcomes are conflicting. One study suggested that clustered TMS maintenance (five sessions over two days, administered once a month) prevented relapse better than no maintenance. Another study reported that a single, monthly TMS session showed no advantage over observation only. There are no clearly recommended stimulus parameters for maintenance TMS. Although the protocol should be individualized according to the clinical picture, a tentative maintenance protocol following a TMS taper (four times weekly for one week, three times weekly for one week, two times weekly for 1–2 weeks) could be one session every two or three weeks for many months to several years depending on the nature of the mood disorder. There is a lack of evidence supporting the long-term, maintenance effects of TMS. Studies are primarily in the form of case reports, case series and retrospective reviews with small patient populations. Controlled studies with increased statistical power, rigorous standards of randomization, blinding procedures, optimal stimulus parameters, and clinical outcome as well as global functioning measures are needed to support the long-term safety and efficacy of maintenance rTMS (Rachid, et al., 2018; Benadhira, et al., 2017; Philip, et al., 2016; Fitzgerald, et al., 2013).

Other proposed forms of administering repetitive TMS (rTMS) to patients with major depression and other psychiatric and neurological conditions include: accelerated rTMS, bilateral rTMS, high-dose rTMS, multifocal, priming LF-rTMS (pTMS) and theta-burst repetitive TMS. In addition, TMS is not recommended for use in the home nor are the devices FDA approved for in-home use.

Although the evidence investigating left dorsolateral prefrontal cortex (DLPFC) repetitive transcranial magnetic stimulation (rTMS) and deep transcranial magnetic stimulation (dTMS) for the treatment of major depressive disorder (MDD) primarily consists of small patient populations and short-term follow-ups, some randomized controlled trials and meta-analysis have reported that TMS had better outcomes than sham therapy and in some studies, outcomes were reported as good as electroconvulsive therapy (ECT) with fewer side effects. As a result, left DLPFC rTMS and dTMS have evolved into an accepted treatment option.

U.S. Food and Drug Administration (FDA): Transcranial Magnetic Stimulation (TMS) systems are FDA 510(k) approved as Class II devices. In July 2011, the FDA issued a Class II TMS guidance detailing special controls that should be combined with general controls to ensure safety and effectiveness of rTMS systems for treatment of patients with MDD.

The standard-of-care FDA approved TMS protocol for treatment of MDD uses repetitive transcranial magnetic pulses applied at a frequency of 10 Hz to modulate cortical excitability. The observed and documented increase in cortical excitability after high frequency (10 Hz rTMS) repetitive TMS (rTMS) has been shown to persist beyond the duration of the train of stimulation, and 10 Hz rTMS on the left dorsolateral prefrontal cortex (L-DLPFC) has been shown to be effective and safe in the treatment of MDD (FDA, 2018).

The Neurostar TMS Therapy® System (Neuronetics, Inc., Malvern, PA) was one of the first systems to be approved by the FDA in 2008. In 2016, the indications for use were updated to state that the "NeuroStar TMS Therapy System is indicated for the treatment of Major Depressive Disorder in adult patients who have failed to receive satisfactory improvement from prior antidepressant medication in the current episode". The NeuroStar Advanced Therapy System was FDA approved November 2020 to perform intermittent theta burst stimulation. In 2024, the FDA approved an expanded indicated population for the NeuroStar System to include adolescent patients (age 15–21) as an adjunct for the treatment of MDD. Based upon real-world data set from the TrakStar database and available published literature, the FDA concluded that TMS is "well tolerated and safe for adolescents" (FDA, 2025).

Examples of other approved TMS devices “indicated for the treatment of major depressive disorder in adult patients who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode” include (FDA, 510(k), 2025):

- Apollo TMS Therapy System
- Brainsway Deep TMS System (Brainsway LTD., Jerusalem, Israel)
- Horizon TMS Therapy System and Horizon TMS Therapy System with Navigation (Magstim Company, Ltd., Philadelphia PA)
- MagVita TMS Therapy with MagPro R20 (Tonica, Elektroni A/S, Farum, Denmark)
- Neurosoft TMS (also called Cloud TMS) (TleEMG, LLC, Salem, NH)
- Nexstim Navigated Brain Therapy (NBT) System 2 (Nexstim Plc. Helsinki, FL)
- NQ TMS for MDD (NQv1-MU-01) (NeuroQore, Inc., Salem, NH)
- Rapid² Therapy System (Magstim Company, LTD., Philadelphia, PA)
- Ultimate rTMS, Yingchi rTMS (Brain Ultimate, Inc., Salem, NH)

Literature Review - left dorsolateral prefrontal cortex repetitive transcranial magnetic stimulation (rTMS): Systematic reviews and randomized controlled trials evaluating the safety and efficacy of left dorsolateral prefrontal cortex repetitive transcranial magnetic stimulation (rTMS) for treatment-resistant, major depressive disorder in adults have been reported. Studies have compared TMS to electroconvulsive therapy (ECT) (Kedzior et al., Mar 2015; Ren, et al., 2014; Berlim et al., 2013b; Minichino, et al., 2012; Keshtkar, et al., 2011; Hansen, et al., 2011; Mcloughlin, et al., 2007; Eranti, et al., 2007; Rosa, et al., 2006) and TMS to sham (Liu, et al., 2014; Gaynes, et al., 2014; Allan, et al., 2011; Ray, et al., 2011; Pallanti, et al., 2010; Schutter, et al., 2009; Lam, et al., 2008; Mogg, et al., 2008; O’Reardon, et al., 2007; Herwig et al., 2007; Fitzgerald, et al., 2006a; Machii, et al., 2006). Prospective case series and randomized control trials have also investigated TMS as a therapeutic option for treatment-resistant depression (Sehatzadeh, et al., 2019; Dunner, et al., 2014; Carpenter, et al., 2012; Mantovani, et al., 2012a; Janicak, et al., 2010; Avery et al., 2008).

Outcome measures varied and included the Clinical Global Impressions-Severity of Illness scale (CGSI), patient reported inventory of Depressive Symptoms Self Report (IDS-SR), 9-Item Patient Health Questionnaire (PHQ-9), Clinical Global Impressions-Severity of Illness Scale (CGI-S), Hamilton Depression Rating Scale (HDRS), Beck Depression Inventory-II, visual analogue mood scales (VAMS), and Brief Psychiatric Rating Scale. Reduction in depressive symptoms, suicide ideation and remission of depression were reported.

Although there are conflicting results, overall improvement or remission of symptoms of depression and/or suicidal tendencies following TMS were reported, especially when TMS was compared to sham. Other studies reported better outcomes with ECT. However, some studies reported that response and remission rates following TMS were as good as ECT with fewer side effects. TMS adverse events, which were typically mild and transient, included headaches and localized discomfort/pain of the scalp during stimulation. In rare cases, seizures and psychotic symptoms were reported following TMS. Studies were limited by small patient populations, short-term follow-ups and heterogeneity of treatment regimens. Additional research is needed to define optimal TMS treatment protocols. Peer-reviewed, published studies supporting TMS as a maintenance therapy are lacking.

Existing peer reviewed literature evaluating the use of rTMS in adolescents consists of systematic reviews and meta-analysis of randomized controlled trials (RCTs), RCTs, and open label studies. Although studies are limited by heterogeneity in treatment parameters, short-term follow-up, and small patient populations, significant improvements have been demonstrated when compared to sham, antidepressant use alone, or sham combined with antidepressant use. Adverse events have been reported as “minor” and include: headache, nausea, constipation, dizzy, loss of appetite,

sweating, and insomnia (Cao, et al., 2023; Sun, et al., 2023; Sigrist, et al., 2022; Croarkin, et al., 2021).

Literature Review – Deep Transcranial Magnetic Stimulation (dTMS): Randomized controlled trials and case series investing deep TMS (dTMS) have reported significant improvement in depressive symptoms and scores following dTMS for treatment-resistant major depressive disorder (Feffer, et al., 2017; Levkovitz, et al., 2015; Rapinesi, et al., 2015; Isserles, et al., 2011; Levkovitz, et al., 2009; Levkovitz, et al., 2007).

Kedzior et al. (Nov 2015) conducted a systematic review and meta-analysis to investigate the acute antidepressant effect that dTMS had on major depression. Data from nine open-label studies (n=162) were included in the meta-analysis. Inclusion criteria were: studies that enrolled at least five patients with a primary diagnosis of a major depressive disorder or episode according to DSM-IV or ICD-10 criteria; administered dTMS treatment with H coils; assessed depression severity using any version of any standardized depression rating scale (e.g., Hamilton Depression Rating Scale, [HDRS]); and reported adequate data to compute effect sizes. The outcome measures included the change in depression scores on Hamilton Depression Rating Scale (HDRS), response rates, remission rates and dropout rates. The majority of studies utilized the H1-coil which induced greater stimulation over the left DLPFC, a high frequency of stimulation (18–20 Hz), intensity of 120% of the resting motor threshold, 1680–3000 stimuli per session applied in 42–75 trains, and 20 stimulation sessions. Compared to baseline HDRS scores, there was a large antidepressant effect after 20 acute, high-frequency DTMS sessions (n=150) (overall mean weighted d=2.04, 95% CI: 1.53–2.55). Overall weighted response rate (n=94) was 60% and varied from 43% to 96%. Response rates were higher in the four studies (n=68) with patients on concurrent antidepressants compared to the two studies (n=26) that used dTMS as a monotherapy. Thirty-five out of 124 patients in eight studies remitted after the acute dTMS treatment. Remission rates varied from 0% to 53% in eight studies and decreased over time. A total of 27 out of 162 patients dropped out with dropout rates varying from 0% to 67%. Limitations of the analysis includes the small patient population, short-term follow-up, lack of a comparator, different cut-off scores used to define remission, and two studies used dTMS as a monotherapy vs four studies that used TMS with as an adjunctive therapy.

Agency for Healthcare Research and Quality (AHRQ): The 2011 comparative effectiveness review on nonpharmacological interventions for treatment-resistant depression (TRD) in adults concluded that comparative clinical research on nonpharmacologic interventions in a TRD population is early in its infancy, and many clinical questions about efficacy and effectiveness remain unanswered. Interpretation of the data was hindered by varying definitions of TRD and the paucity of relevant studies. The greatest volume of evidence was for ECT and rTMS. However, the strength of the evidence was low for beneficial outcomes. ECT and rTMS did not produce different clinical outcomes in TRD, and ECT produced better outcomes than pharmacotherapy. No trials directly compared the likelihood of maintaining remission for nonpharmacologic interventions. The few trials addressing adverse events, subpopulations, subtypes, and health-related outcomes provided low or insufficient evidence of differences between nonpharmacologic interventions (Gaynes, et al., 2011).

Department of Veterans Affairs/Department of Defense (VA/DoD): In a clinical practice guideline for the management of MDD (2022), the VA/DoD gave a “weak” recommendation for the use of TMS for “patients who have demonstrated partial or no response to two or more adequate pharmacologic treatment trials”. The work group indicated that the quality of evidence is very low with limitations including: “small study effects, higher than optimal discontinuation, lack of measurement for allocation concealment, and/or other issues”. However, they concluded that the benefits of rTMS outweigh the harms.

Technology Assessments: A 2016 (reviewed 2018) Hayes technology brief on low frequency rTMS (LFrTMS) (1 Hz) included seven randomized controlled trials (n=26–170). The studies reported that LFrTMS, in addition to pharmacotherapy, produced antidepressant effects. However, results were mixed suggesting no difference between LFrTMS and sham therapy as an adjuvant therapy to antidepressant treatment. Results also suggested that there was no difference between LFrTMS and HFrTMS as an add-on therapy. The low-quality evidence did not allow definitive conclusions regarding the efficacy of LFrTMS as a monotherapy. The therapies appeared safe with mild adverse events (e.g., scalp discomfort, transitory headaches).

In a 2016 (updated 2020), directory report on comparative effectiveness of HFL-rTMS, Hayes reported that there was insufficient evidence to support the use of HFL-rTMS combined with ECT compared to ECT alone for treatment-resistant major depressive disorder. The conclusion was based on ten randomized controlled trials with small patient populations (n=32–121). Various outcome criteria and treatment regimens for rTMS and ECT were used. The 2020 published review added six newly published studies that met the original inclusion criteria. With this new information, there was no change to Hayes recommendation.

Professional Societies/Organizations:

American Psychiatric Association (APA): The 2010 American Psychiatric Association (APA) Practice Guideline for the Treatment of Patients with Major Depressive Disorder stated that evidence for TMS is currently insufficient to support its use in the initial treatment of major depressive disorder. Electroconvulsive therapy (ECT) remains the treatment of best-established efficacy against which other stimulation treatments (e.g., VNS, deep brain stimulation, TMS, other electromagnetic stimulation therapies) should be compared. A substantial number of studies of TMS have been conducted, but most have had small sample sizes, and the studies overall have yielded heterogeneous results. Further complicating the interpretation of the TMS literature is the variability in stimulation intensities (relative to the motor threshold), stimulus parameters (e.g., pulses/second, pulses/session), anatomical localization of stimulation, and number of TMS sessions in the treatment course. As an initial treatment in the acute phase of major depression the guideline reported that the goal of treatment in the acute phase should be aimed at remission of the major depressive episode and achieving a full return to the patient's baseline level of functioning. Acute phase treatment may include pharmacotherapy, depression-focused psychotherapy, combination therapies (e.g., medications and psychotherapy, or other somatic therapies such as ECT, TMS, or light therapy) (APA, 2010). There has been no update to this guideline since 2010.

Clinical TMS Society: In a coverage guidance document, the Clinical TMS Society addresses the use of TMS for the treatment of MDD in adolescents with the following statement: "TMS for adolescents with MDD may be appropriate and should be considered on a case-by-case basis, if there is a high level of treatment resistance, and the patient meets all criteria for TMS other than age. These cases should be reviewed individually for medical necessity and considered for compassionate use." This coverage guidance document hasn't been updated since 2021 with the emergence of additional literature, data, and FDA clearances (Clinical TMS Society, 2021).

Transcranial Magnetic Stimulation for Obsessive-Compulsive Disorder (OCD):

Obsessive-Compulsive Disorder (OCD) is a common, chronic and long-lasting disorder. It is mainly characterized by obsessions, which are persistent and intrusive thoughts, urges or images that an individual finds distressing, and compulsions, which are repetitive, time-consuming behaviors or mental acts usually performed to prevent or reduce distress. OCD manifests as a heterogeneous clinical condition with the intensity and mix of obsessions and compulsions varying between patients. OCD can be severely incapacitating and associated with impaired social and occupational functioning, and reduced quality of life. OCD is typically diagnosed by age 19 years, but onset is

also seen after age 35 years. The causes of OCD are unknown. Genetic and environmental factors are believed to contribute to the etiology of OCD (Cocchi, et al., 2018; Rehn, et al., 2018; National Institute of Mental Health, 2016, Updated 2025).

Treatment for OCD includes medication (selective serotonin reuptake inhibitor [SSRI], antidepressants, clomipramine, venlafaxine), psychotherapy (cognitive behavioral therapy) or a combination of both. Treatment-resistant OCD patients are defined as those who undergo satisfactory trials of first-line treatments without showing an adequate response, usually defined by a reduction in Yale-Brown Obsessive Compulsive Scale (Y-BOCS) score $\geq 25\%$ with respect to baseline. For individuals who are resistant to pharmacotherapy, transcranial magnet stimulation has been investigated, and studies have reported favorable clinical outcomes (Rehn, et al., 2018; National Institute of Mental Health, 2016, updated 2025).

U.S. Food and Drug Administration (FDA): The Brainsway Deep Transcranial Magnetic Stimulation System (Brainsway Ltd., Kfar Saba, Israel) was FDA approved on August 17, 2018 as a class II De Novo device. The Food and Drug Administration Modernization Act of 1997 (FDAMA) added the De Novo classification option, also known as Evaluation of Automatic Class III Designation, to provide an alternate pathway to classify novel devices of low to moderate risk that are not substantially equivalent to an existing FDA approved device (predicate device). Devices that are classified through the De Novo process may be marketed and used as predicates for future 510(k) submissions and are typically Class II devices. The Brainsway System is FDA approved "to be used as an adjunct for the treatment of adult patients suffering from Obsessive-Compulsive Disorder" (FDA, 2025; FDA, 2025b).

According to the Manufacturer, the device was FDA approved on a multicenter randomized controlled trial of 94 patients who previously failed pharmacological or psychological treatment. Subjects received thirty-minute sessions, five times per week, over a course of six weeks with the Brainsway H7-deep-TMS system. The primary outcome measure was the OCD Yale-Brown Obsessive Compulsive Scale (Y-BOCS). Following the six-week treatment session, there was a statistically significant improvement in the Y-BOCS score for the active treatment group compared to sham ($p=0.0157$). In addition, 38.1% of patients in the active group achieved a response compared with 11.1% in the sham group ($p=0.0033$) and 54.8% of patients in the active group achieved a partial response versus 26.7% in the sham group ($p=0.0076$). The improved clinical effect in Y-BOCS scores was maintained in the active group one month following treatment. Improvement was more pronounced than that achieved in the sham group ($p=0.0459$) (Brainsway Ltd, 2017).

Examples of other FDA approved TMS devices for the treatment of or adjunct treatment of obsessive-compulsive disorder include (FDA 510(k), 2025):

- BTL-99-OC (BTL Industries, Inc., Marlborough, MA)
- CloudTMS for OCD (TeleEMG, LLC, Salem, NH)
- Magstim Horizon 3.0 TMS Therapy System, Horizon 3.0 System, Horizon 3.0, H3.0, Horizon 3.0 with StimGuide+ (Magstim Company Ltd., Whitland, Carmarthenshire, UK)
- MagVenture TMS Therapy System (Tonica Elektronik A/S, Farum, Denmark)
- NeuroStar Advanced Therapy System (Neuronetics, Malvern, PA)

Literature Review – FDA Approved Devices for OCD: Studies investigating the safety and efficacy of TMS using an FDA approved device for the treatment of OCD are in the form of systematic reviews, randomized controlled trials, case series, case reports and retrospective reviews. Overall short-term results have reported statistically significant improvements in YBOCS scores when applying rTMS over the bilateral dorsolateral prefrontal cortex (B-DLPFC), right-DLPFC (R-DLPFC) and the supplementary motor area (SMA), along with applications with both LF-rTMS ($p=0.001$) and HF-rTMS ($p=0.01$). No serious adverse events have been identified in these

studies. Therefore, TMS for the treatment of OCD is evolving into an accepted treatment option for this disease.

Carmi et al. (2019) conducted a prospective multicenter, randomized, double-blind, placebo-controlled trial (n=100, aged 22-69 years) to examine the therapeutic effect of deep TMS (dTMS) for patients diagnosed with obsessive-compulsive disorder. Deep TMS was administered using a Magstim Rapid2 TMS stimulator equipped with a unique H7, H-shaped coil design. When placed four centimeters anterior to the foot motor cortex and used at 100% of the leg resting motor threshold (RMT), the H7 coil stimulated the dorsal medial prefrontal cortex (mPFC) and anterior cingulate cortices (ACC) bilaterally. The active treatment group received 20 Hz dTMS at 100% of RMT, with two-second pulse trains and 20-second intertrain intervals, for a total of 50 trains and 2,000 pulses per session. At the posttreatment assessment, YBOCS decreased significantly from baseline in both the active (-6.0 points, 95% CI=4.0, 8.1) and sham (-3.3 points, 95% CI=1.2, 5.3). The difference in slopes of change in YBOCS score between the two groups was 2.8 points (p=0.01). At the one-month follow-up, YBOCS score had decreased by 6.5 points (95% CI=4.3, 8.7) in the active treatment group and by 4.1 points (95% CI=1.9, 6.2) in the sham treatment group (p=0.03). The rate of full response (a reduction \geq 30% in YBOCS score) at the posttreatment assessment in the active treatment group was 38.1% (16/42), compared with 11.1% (5/45) in the sham treatment group (p=0.003).

Literature Review – FDA Approved Devices not Indicated for OCD: Additional studies have been conducted using TMS devices that are not FDA approved for OCD (Rapinesi, et al., 2019; Rehn, et al., 2018; Zhou, et al., 2017; Elbeh, et al., 2016; Pelissolo, et al., 2016; Trevizol, et al., 2016; Berlim, et al., 2013c). Limitations of the studies include: small patient populations, heterogeneity of treatment parameters, little or no follow-up after treatment, and heterogeneity of stimulation parameters and cortical targets. Outcomes are conflicting and inconclusive. Only an FDA approved device should be used to administer TMS for OCD.

Transcranial Magnetic Stimulation for Migraine

The Cerena Transcranial Magnetic Stimulator (TMS) (eNeura Therapeutics, Sunnyvale, CA) device is the same device as the Spring TMS™ Total Migraine System marketed by eNeura Therapeutics in Europe. The device is small enough to be placed inside a large purse and can be used in the home or office where a comfortable chair or couch is available to the individual during use. The individual activates the subscriber information module (SIM) chip inside his or her prescription card for the device. The chip works only with the individual's device, and the prescription must be renewed regularly. When the individual experiences the onset of a migraine attack, the individual places the device on a flat surface in the "on" mode, presses the power button, and places the device behind the head at the base of the skull. The device has folding handles, which the individual can hold during treatment. When in place, the individual slides the treatment delivery switches housed in the handles to administer a pulse; a second pulse completes the treatment in less than a minute. The system automatically records the treatment history and is used with a headache diary program on a personal computer. Both the treatment history and headache diary can be uploaded to an online journal on the eNeura Therapeutics website. The device uses single-pulse transcranial magnetic stimulation (sTMS).

U.S. Food and Drug Administration (FDA): The Cerena Transcranial Magnetic Stimulator (TMS) (eNeura Therapeutics, Sunnyvale, CA) received FDA 510(k) approval via the de novo premarket review pathway. This is the first approved device proposed to relieve pain caused by migraine headaches that are preceded by an aura: a visual, sensory or motor disturbance immediately preceding the onset of a migraine attack (FDA, 2013). In 2016, eNeura received a Class II FDA 510(k) approval for the sTMS mini device. Per the FDA approval, "the sTMS mini is indicated for the acute treatment of pain associated with migraine headache with aura. The device is designed for patient use where treatments are self-administered and can be delivered in a

variety of settings including the home or office" (FDA, 2016). The device is available by prescription only. The SpringTMS was FDA approved February 2019 for "the acute and prophylactic treatment of migraine headache in adolescents (age 12 and older) and adults (FDA, 2025).

On May 16, 2023, the prescription only SAVI Dual™ Migraine Therapy device (eNeura, Inc., Orono, MN) received 510(k) approval for the "acute and prophylactic treatment of migraine headache in adolescents (age 12 and older) and adults".

Literature Review: There are a limited number of peer-reviewed published studies exploring the efficacy of TMS for the treatment of pain associated with migraine headaches. Methodological limitations of these studies include small sample sizes, limited follow-up intervals and high dropout rates. Additional randomized controlled trials are needed to determine optimal treatment parameters, including the range of doses and timing of treatment, to confirm the effectiveness and durability of TMS for the treatment of pain associated with migraine headaches (Rapinesi, et al., 2016; Misra, et al., 2012; Brighina, et al., 2004; Teepker, et al., 2010; Clarke, et al., 2006; Brighina, et al., 2004).

Lan et al. (2017) conducted a systematic review and meta-analysis of randomized controlled trials (RCT) to investigate the efficacy of TMS for the treatment of migraine headaches. To be included, the study had to be an RCT with quantitative outcomes. Five studies (n=313) met the inclusion criteria. Four studies included chronic migraine subjects, and one study (n=164) investigated TMS for the acute treatment of migraine with aura. Data from the one study (Lipton, et al., 2010) reported that single-pulse TMS was significantly effective for the acute treatment of migraine with aura after the first attack ($p=0.02$). There was no statistically significant difference in effect between the active TMS group and sham TMS group for the treatment of chronic migraine ($p=0.14$). Author-noted limitations of the meta-analysis included: limited number of studies; small patient populations; possibility of publication bias; heterogeneity of treatment regimens including site stimulated; doses that improved headache were not identifiable; lack of a standard control group (sham and botulinum toxin-A injection); no comparison to conventional therapy; and subjects primarily came from general hospitals or major institutions limiting generalization to the general population.

The FDA clearance of the Cerena TMS device was based on a single multi-center randomized, double-blind, parallel-group, two-phase, sham-controlled study (Lipton, et al., 2010). Adults who met the International Classification Headache Disorders criteria for migraine headache with aura ranged in age from 18-70 years. Phase one of the trial enrolled 267 adults who experienced visual aura preceding at least 30% of migraines, followed by moderate or severe headache in more than 90% of those attacks. Participants in phase one were trained to use an electronic diary to verify prospectively the diagnosis of migraine with aura. Sixty-six participants (25%) dropped out after phase one of the trial. In phase two, 201 individuals randomized to either sham stimulation (n=99) or sTMS (n=102) self-applied the device to the back of the head, pressing a button to administer two pulses, each approximately 0.9 Tesla and lasting less than a millisecond, 30 seconds apart. Participants were instructed to treat up to three attacks over three months while experiencing aura. The primary outcome measure was pain-free response two hours after the first attack. Thirty-seven participants did not treat a migraine attack and were excluded from the outcome analyses. A total of 164 participants treated for at least one attack of migraine with aura with sTMS (n=82) or with sham stimulation (n=82) reported that pain-free response rates two hours after stimulation were significantly higher with sTMS (39%, 32 of 82) than with sham stimulation (22%, 18 of 82; $p=0.018$). Sustained pain-free response rates with no recurrence and no rescue drug use significantly favored sTMS at 24 hours (29% [24 of 82] versus 16% [13 of 82]; $p=0.0405$) and 48 hours (27% [22 of 82] versus 13% [11 of 82]; $p=0.0327$) after treatment. There were no significant differences in secondary outcomes (headache response at two hours, use of rescue drugs, Migraine Disability Assessment [MIDAS] score and consistency of

pain relief response) between groups. The study did not demonstrate that sTMS was effective in relieving the associated symptoms of migraine, including nausea, photophobia, and phonophobia. No device-related serious adverse events were reported. Limitations of this study include the high dropout rate during phase one of the trial (25%, 66 of 267), the potential for unblinding of the device after administration of treatment, and variations in the time intervals from the onset of aura to treatment and pain intensity at the time of treatment. Additional randomized controlled trials are needed to determine optimal treatment parameters, including the range of doses and timing of treatment, to confirm the safety and durability of sTMS for the treatment of pain associated with migraine headache with aura.

In a Prognosis Overview on Cerna, Hayes (2014) concluded that there was insufficient published evidence to draw conclusions regarding the efficacy of this device for the treatment of migraine headaches. The best available study was the Lipton et al. (2010) study discussed above.

Transcranial Magnetic Stimulation - Other Psychiatric or Neurological Disorders

Literature Review

There have been numerous studies and meta-analyses conducted that explored the efficacy of TMS for a selection of neuropsychiatric-related disorders. Some of the methodological limitations of these studies include small patient populations, short-term follow-ups, variability in technique and outcome measures, and varied diagnostic groups on and off pharmacotherapy. Also, the optimal TMS protocol have not been identified for these conditions. Therefore, the clinical utility and improvement in health outcomes of TMS in the treatment of other psychiatric or neurological disorders have not been clearly established. TMS has not been proven effective in the peer-reviewed published scientific literature for the following indications nor are the devices FDA approved for these conditions:

- addictions (Torres-Castaño, et al., 2021; Zhang, et al., 2019; Maiti, et al., 2017; Grall-Bronnec and Sauvaget, 2014)
- alcohol dependence (Mishra, et al., 2010)
- Alzheimer disease (Wang, et al., 2020; Lin, et al., 2019; Hayes, 2018, updated 2019; Liao, et al., 2015; Ahmed, et al., 2012; Cotelli, et al., 2011)
- amyotrophic lateral sclerosis (ALS) (Fang, et al., 2013; Di Lazzaro, et al., 2010)
- anorexia nervosa (McClelland, et al., 2016)
- anxiety disorder (Parikh, et al., 2022; Diefenbach, et al., 2016)
- attention deficit hyperactivity disorder (ADHD) (Bloch, et al., 2010)
- auditory hallucinations in schizophrenia (Li, et al., 2020; Freitas, et al., 2012; Slotema, et al., 2011; Cordes, et al., 2010; Loo, et al., 2010; Dlabac-de Lange, et al., 2010; Freitas, et al., 2009; Fitzgerald, et al., 2005; Schonfeldt-Lecuona, et al., 2004; Hoffman, et al., 2003; Aleman, et al., 2007)
- autism (Sokhadze, et al., 2010)
- bipolar depression (VA/DoD, 2023b; Nguyen, et al., 2021; Bulteau, et al., 2019)
- blepharospasm (Kranz, et al., 2010; Kahn, et al., 2010)
- bulimic disorders (Van den Eynde, et al., 2010)
- chronic pain (O'Connell, et al., 2018; Jin, et al., 2015; Galhardoni, et al., 2015; Boldt, et al., 2014; Taylor, et al., 2012; Sampson, et al., 2011)
- chronic tinnitus (Noh, et al., 2019; Folmer, et al., 2015; Meng, et al., 2011; Anders, et al., 2010; Lorenz, et al., 2010; Frank, et al., 2010; Marcondes, et al., 2010; Landgrebe, et al., 2008; Khedr, et al., 2008; Rossi, et al., 2007; Kleinjung, et al., 2005; De Ridder, et al., 2005; Plewnia, et al., 2003)
- children (Allen, et al., 2017)
- epilepsy (Walton, et al., 2021; Pereira, et al., 2016; Chen, et al., 2021; Brodbeck, et al., 2010)
- facial pain (Ferreira, et al., 2019; Hodaj, et al., 2015)

- fibromyalgia (Saltychev and Laimi, 2017; Knijnik, et al., 2016; Marlow, et al., 2013)
- focal dystonia (Schneider, et al., 2010)
- Huntington's disease (Medina, et al., 2010)
- multiple sclerosis (Korzhova, et al., 2019)
- neuropathic pain (Attal, et al., 2021; Kim, et al., 2020)
- obesity (Ferrulli, et al., 2019)
- panic disorder (Li, et al., 2014; Mantovani, et al., 2012b)
- Parkinson's disease (Li, et al., 2020b; Xie, et al., 2020; Trung, et al., 2019; Chung and Mak, 2016; Wagle, et al., 2016; Chou, et al., 2015; Shiota, et al., 2013; Benninger, et al., 2011; Arias, et al., 2010; Hartelius, et al., 2010; Pal, et al., 2010; Filipović, et al., 2010; Fregni, et al., 2004)
- postherpetic neuralgia (Pei, et al., 2019; Ma, et al., 2015)
- post-concussion syndrome (VA/DoD, 2021; Moussavi, et al., 2019)
- post-operative pain (Borckardt, et al., 2006; Khedr, et al., 2005)
- post-stroke aphagia (Li, et al., 2015)
- post-stroke aphasia (Ren, et al., 2019)
- post-stroke dysphagia (Zhong, et al., 2023; Ünlüer, et al., 2019; Du, et al., 2016)
- post-traumatic stress disorder (Brown, et al., 2024; Philip, et al., 2019; VA/DoD, 2023; Yan, et al., 2017; Trevizon, et al., 2016; Berlim and Eynde, 2014; Karsen, et al., 2014; Boggio, et al., 2010; Cohen, et al., 2004)
- schizophrenia (VA/DoD, 2023; Kumar, et al., 2020; He, et al., 2017; Wobrock, et al., 2015; Dougall, et al., 2015; Quan, et al., 2015; Bais, et al., 2014; Blumberger, et al., 2010; Matheson, et al., 2010; McNamara, et al., 2001)
- smell and taste dysfunction (Henkin, et al., 2011)
- spinal cord injury (Nardone, et al., 2015; Awad, et al., 2013; Soler, et al., 2010; Kumru, et al., 2010)
- stroke (Xu, et al., 2021; He, et al., 2020; Tung, et al., 2019; VA/DoD, 2024; Dos Santos, et al., 2019; Xiang, et al., 2019; Dionísio, et al., 2018; Zhang, et al., 2017; Graef, et al., 2016; Zheng, et al., 2015; Avenanti, et al., 2012; Corti, et al., 2012; Weiduschat, et al., 2011; Emara, et al., 2010; Takeuchi, et al., 2010; Chang, et al., 2010; Kim, et al., 2010; Khaleel, et al., 2010; Lim, et al., 2010; Khedr, et al., 2009, 2010; Fregni, et al., 2006)
- tardive syndromes (Khedr, et al., 2019)
- tension-type headache (VA/DoD, 2023c; Mattoo, et al., 2019)
- tic disorders (Wu, et al., 2014; Steeves, et al., 2012; Kwon, et al., 2011)
- tinnitus (VA/DoD, 2024; Galal, et al., 2020; Soleimani, et al., 2016)
- Tourette syndrome (Landeros-Weisenberger, et al., 2015)

The Brainsway Deep TMS System and modified Brainsway Deep (DTMS) System (Brainsway Ltd, Jerusalem IL) are FDA approved "to be used as an aid in short-term smoking cessation for adults". Both use an H4/HADD-Coil to deliver 120% of the patient's observed motor threshold for 10 Hz to the prefrontal cortex and insula (FDA, 2025).

In 2022, both the BrainsWay Deep TMS™ System and the NeuroStar line of devices received 510(k) approval for the "treatment of depressive episodes and for decreasing anxiety symptoms for those who may exhibit comorbid anxiety symptoms in adult patients suffering from Major Depressive Disorder (MDD) and who failed to achieve satisfactory improvement from previous antidepressant medication treatment in the current episode (FDA, 2025).

In evidence-based guidelines for the treatment of tinnitus, the American Academy of Otolaryngology—Head and Neck Surgery Foundation (AAO-HNSF) recommended against the use of TMS for the routine treatment of persistent, bothersome tinnitus. The recommendation was based on inconclusive data from randomized controlled trials (Tunkel, et al., 2014).

In a meta-analysis, Slotema et al. (2010) examined if rTMS is effective for various psychiatric disorders. Data were obtained from randomized, sham-controlled studies of rTMS treatment for depression (34 studies, n=751 rTMS and n=632 sham), auditory verbal hallucinations (AVH, seven studies), negative symptoms in schizophrenia (seven studies), and obsessive-compulsive disorder (OCD, three studies). Studies included a comparison of rTMS versus electro-convulsive therapy (ECT, six studies) for depression. Standardized mean effect sizes of rTMS versus sham were computed based on pre-treatment versus post-treatment comparisons. The mean weighted effect size of rTMS versus sham for depression was 0.55 ($p<0.001$). Monotherapy with rTMS was more effective than rTMS as adjunctive to antidepressant medication. ECT was superior to rTMS in the treatment of depression (mean weighted effect size -0.47, $p=0.004$). In the treatment of AVH, rTMS was superior to sham treatment, with a mean weighted effect size of 0.54 ($p<0.001$). The mean weighted effect size for rTMS versus sham in the treatment of negative symptoms in schizophrenia was 0.39 ($p=0.11$) and for OCD, 0.15 ($p=0.52$). Side effects were mild, yet more prevalent with high frequency rTMS at frontal locations. The authors stated that although the efficacy of rTMS in the treatment of depression and AVH may be considered proven, the duration of the effect is as yet unknown. Effect sizes were measured immediately after the cessation of rTMS treatment. There are indications that the effects of rTMS may last for several weeks to months. The authors reported that although rTMS cannot replace ECT in depressive patients, there may be subgroups in which rTMS can replace antidepressant medication.

Other Forms of Transcranial Magnetic Stimulation

Accelerated TMS (aTMS): aTMS refers to the administration of multiple sessions per day (e.g., 2–5) for less than four weeks in an effort to intensify antidepressant response. Some of the advantages of accelerated TMS are to improve accessibility by reducing disruption in daily living and commuting requirements.

Studies include RCTs, self-controlled, and open label studies with small patient populations (n=4–115) and two days to three weeks treatment sessions followed or not followed by conventional rTMS. Outcomes are conflicting and, in some cases, report that aTMS is not more effective than sham or standard TMS. Studies are further limited by heterogeneous treatment parameters and short-term follow-up (i.e., three weeks to three months). Accelerated TMS has also been proposed for the treatment of attention deficit hyperactivity disorder (ADHD), alcohol addiction and suicidal patients (Shi, et al., 2024; Fitzgerald, et al., 2018; Brunoni, et al., 2017; Theleritis, et al., 2017; Tor, et al., 2016; McGirr, et al., 2015; Baeken, et al., 2013; Holzheimer, et al., 2010; Loo, et al., 2007).

Fitzgerald, et al. (2018) conducted a parallel, randomized controlled trial (n=115) to evaluate outcomes achieved with an accelerated rTMS protocol compared to a standard rTMS protocol in patients with MDD. The mean age of participants was 49 ± 13.8 years and 66 were female. Participants were eligible for inclusion if they had a diagnosis of treatment resistant MDD. Participants were excluded if they: had a contraindication to TMS (e.g., metallic implants in the head, cardiac pacemakers, cochlear implants, or other implanted electronic devices), started a new antidepressant treatment within the preceding four weeks, had another Axis 1 psychiatric disorder, had a history of substance abuse or dependence in the preceding six months, or had a neurodegenerative disorder. The accelerated rTMS protocol consisted of three weeks of decreasing treatment intensity administered to the left DLPFC. Week one included three times daily treatment sessions for three days, week two included three treatment sessions over two days, and week three included three treatment sessions given in a single day. Sessions occurring on the same day were provided 15–30 minutes apart. The comparator consisted of a standard, daily treatment protocol provided in 20 daily sessions, five days per week, over four weeks. Outcome measures used were the Montgomery Asberg Depression Rating Scale (MADRS), the Beck Depression Inventory II (BDI), the Scale of Suicidal Ideation (SSI), and the Hamilton Depression Rating Scale (HDRS-17). Positive responses from the HDRS-17 and MADRS scales were defined as $> 50\%$

reduction in scores. Remission was defined as < 8 on the HDRS-17 or < 10 on the MADRS. Cognitive function (i.e., attention, speed of information processing, verbal and visual memory, and executive function) were assessed using the Digit Span, Digit Symbol Coding, Trail Making Test, Rey Verbal Auditory Learning Test, Stroop, Verbal Fluency, Brief Visuospatial Memory Test, and the Rey Complex Figure. Participants were assessed at baseline and at the end of weeks one, two, three, four, and eight. Out of the 115 participants included in the analysis, 111 completed baseline and at least week four assessments. Three participants withdrew in the accelerated treatment group, and one withdrew from the standard group. There were no differences in baseline scores for any domain. There were no significant differences in response or remission rates between the two groups on the HDRS-17 at four weeks or on the MADRS at four and eight weeks. A significant reduction in MADRS scores was observed in the accelerated group from baseline to week one ($p<0.001$) and from week one to week 2 ($p<0.05$) but not at any of the other time points. A significant reduction in MADRS scores was observed in the standard group from baseline to week one, three, and four ($p<0.001$, $p<0.01$, $p<0.01$ respectively). Significantly more participants in the accelerated group reported site discomfort compared to the standard group ($p=0.01$). More participants in the accelerated group ($n=16$) experienced headache following at least one treatment session compared to the standard group ($n=9$). Author noted limitations of the study included the non-blinding of participants and small sample size obtained from a single site. An additional limitation of the study is the short-term follow-up.

Theleritis, et al. (2017) conducted a parallel-group, randomized, sham controlled trial ($n=96$) from a single center to evaluate the efficacy of two high-frequency rTMS sessions per day compared to one for the treatment of MDD. Individuals were eligible for inclusion if they: were 18–59 years old; were right-handed; had a diagnosis of treatment resistant nonpsychotic MDD; had never undergone TMS before; were not pregnant, and did not have a history of seizures, head injury with loss of consciousness, brain surgery, metallic implants, dementia, or substance dependence or abuse within the previous six months. Participants were encouraged to discontinue the use of antidepressants prior to entry into the study. However, if this was not possible, participants were kept on a minimum antidepressant regimen and kept stable for a minimum of four weeks before study entry. The intervention consisted of high-frequency rTMS (Magstim ultrarapid stimulator; Magstim Company Ltd, Whitland, UK) delivered with a figure-8 coil to the left prefrontal cortex consecutively on weekdays (starting on Monday) either one time per day (A1 group; $n=27$) or two times per day (A2 group; $n=27$) that continued for three weeks for a total of either 15 (A1) or 30 (A2) treatment sessions. Sham rTMS (i.e., lateral edge of an active coil was rotated 90 degrees away from the scalp) delivered on weekdays either one time per day (S1 group; $n=20$) or two times per day (S2; $n=24$) that continued for three weeks served as the comparator. Outcome measures used were the Hamilton Depression Rating Scale (HDRS) and the Clinician Global Impressions-Severity of Illness (CGI-S). HDRS response was defined as a decrease of 50% or more from baseline and remission as a score of < 8 . CGI-S response was defined as an endpoint rating of ≤ 3 and remission as a score of ≤ 2 . Patients were evaluated at baseline, at the end of the first, second, and third weeks of treatment, and again after treatment sessions were complete at the fifth week. Nine participants did not complete the trial due to: protocol violation, exacerbation of a preexisting headache, inability to attend treatment sessions because of work or financial reasons, and hospitalization with influenza. Analysis took place on the intent-to-treat sample ($n=96$). Differences in baseline measures were not significant between the four groups. Significant improvement in the HDRS and CGI-S scores were noted in the active treatment group compared to the sham group ($p<0.001$). The likelihood of remission in the active treatment groups was found to be significantly associated with baseline scores ($p=0.001$) but not significantly associated with the number of rTMS sessions per day ($p=0.066$). Adverse events included discomfort at the site of stimulation and exacerbation of a preexisting headache in both the active in sham groups. Author noted limitations of the study included: non-blinding of the individuals administering treatment, absence of a sham coil capable of delivering rTMS-like sensations, the fact that the authors did not evaluate the impact rTMS has on cognitive function, and short-term follow-up. Additional limitations of the study include the unknown effect

pharmacotherapy had on outcomes. Additional, well-designed studies are needed to evaluate the safety and efficacy of rTMS delivered more than one time per day.

Bilateral Transcranial Magnetic Stimulation: Bilateral TMS combines high frequency stimulation of the left dorsolateral prefrontal cortex (DLPFC) with low frequency stimulation of the right DLPFC (either simultaneously or sequentially) during one TMS session. It is hypothesized that stimulation of each side may activate complementary mechanisms that would enhance efficacy. Bilateral TMS has been proposed for the treatment of treatment-resistant major depressive disorder, attention deficit hyperactivity disorder (ADHD), stroke, schizophrenia, tinnitus, and Parkinson's disease (Brunoni, et al., 2017; Zhang, et al., 2015; Chen, et al., 2014).

Overall, systematic reviews, meta-analysis, randomized controlled trials and comparative studies have reported that sequential bilateral rTMS is not more effective than unilateral rTMS. Galletly et al. (2017) conducted a comparative study to assess the effectiveness of sequential bilateral rTMS (n=57) and right unilateral rTMS (n=78) for the treatment of depression. There were no statistically significant differences in response and remission rates between the two groups. The authors concluded that right unilateral rTMS may be a better choice than bilateral treatment given the shorter treatment time and the greater safety and tolerability of unilateral TMS. In a randomized controlled trial comparing the efficacy of sequential bilateral rTMS to right-sided unilateral rTMS using a priming protocol (n=179), the authors concluded that the results of the study did not support superior efficacy of bilateral rTMS (Fitzgerald, et al., 2013b).

Blumberger et al. (2016) conducted a randomized controlled trial (n=121) comparing sequential bilateral rTMS (n=40) (600 pulses at 1 Hz followed by 1500 pulses at 10 Hz), unilateral high-frequency left (HFL)-rTMS (n=40) (2100 pulses at 10 Hz) or sham rTMS (n=41) for 3 or 6 weeks depending on treatment response. Stimulation was targeted with MRI localization over the junction of the middle and anterior thirds of the middle frontal gyrus, using 120% of the coil-to-cortex adjusted motor threshold. The primary outcome measure was the remission rate. Remission rates differed significantly among the three groups: 8/40 (20%) subjects in the bilateral group; 3/40 (7.5%) in the unilateral group; and 1/41 (2.4%) in the sham group (p=0.027). Response rates did not differ significantly between the three groups. Regarding dropout rates, four occurred (10.0%) in the bilateral group, seven (17.5%) in the unilateral group and five (12.1%) in the sham group. Headache was the most frequently reported adverse event (n=21) followed by pain (seven subjects in the bilateral group, eight in the unilateral group and two in the sham group). Limitations of the study include the small patient populations, short-term follow-ups and concurrent use of antidepressants by most subjects during the trial. The authors noted that this was the first RCT comparing sequential bilateral and unilateral rTMS using cortical co-registration, adjusting intensity for coil-to-cortex distance and providing up to six weeks of treatment. There was no statistically significant difference in overall depression change scores. Enhanced efficacy rates were not seen using the enhanced techniques of adjusting MT for coil-to-cortex distance or MRI targeting of the DLPFC.

Zhang et al. (2015) conducted a systematic review and meta-analysis of ten randomized controlled trials (n=634) to evaluate the efficacy of bilateral TMS compared with unilateral rTMS and sham rTMS in patients with treatment resistant depression (TRD). Inclusion criteria were as follows: subjects had a diagnosis of adult MDD based on the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV, DSM-III or DSM-III-R) or the International Classification of Diseases (ICD-9 or ICD-10) criteria and had failed to respond to at least one course of adequate treatment for MDD during the current illness episode. Treatment resistant patients with comorbid neurological disorders and psychotic disorders or specific types of depression (e.g., child and adolescent depression or postpartum depression) were excluded. The primary outcome was the change in depression scores at the end of treatment. Remission was the secondary outcome. The cut-off points of response were $\geq 50\%$ from the baseline score to the end of treatment score on the Hamilton Depression Rating Scale (HDRS) or the Montgomery and Asberg Depression Rating

Scale (MADRS), or “much improved” or “very much improved” on the Clinical Global Impression (CGI) scale. Clinical remission was defined as a depression rating scale score within the normal range at the end of treatment. Three trials investigated unilateral rTMS, four evaluated sham rTMS, and three assessed both unilateral and sham rTMS. Treatment duration was 1–6 weeks. The primary and secondary outcomes of bilateral rTMS showed no significant improvements in outcomes compared to unilateral rTMS ($p=0.22$). There was a significant improvement in the change in depression scores at the end of treatment for bilateral rTMS compared to sham, but not for bilateral compared to unilateral. Limitations of the study include the limited number of studies and small patient populations. The data from this meta-analysis showed that bilateral rTMS is not a useful treatment for patients with TRD.

Chen et al. (2014) conducted a systematic review and meta-analysis to compare the efficacy of bilateral vs. unilateral repetitive transcranial magnetic stimulation (rTMS) in the treatment of major depressive disorder (MDD). Seven randomized controlled trials (RCTs) ($n=509$) met inclusion criteria. RCTs were included that investigated MDD patients aged 18 years or older without metallic implants or foreign bodies, epileptic seizures, severe suicidal risk, substance abuse, alcohol or drug dependence and had a mood assessment by the Hamilton Depression Rating Scale (HDRS), the Montgomery–Asberg Depression Rating Scale (MADRS), or the Clinical Global Impression (CGI). The primary outcome measures were the response rate and remission rate. The response rate was 117/248 in bilateral subjects and 120/261 in unilateral subjects showing no significant difference ($p=0.86$) between the two types of TMS at three- and six-weeks follow-up. Five RCTs reported remission rates. A total of 75/214 bilateral subjects and 71/213 unilateral subjects remitted showing no significant difference ($p=0.09$) between the groups. No significant difference was seen in the drop-out rates (bilateral subjects 29/219 vs. 38/232 unilateral subjects). Limitations of the studies include the small patient populations, short-term follow-ups, and heterogeneity of the patient populations. The authors noted that bilateral TMS usually involves a greater number of stimuli than unilateral, and the efficacy of bilateral may be the result of the number of stimulation pulses vs. the bilateral nature. Additional large-scale randomized trials are needed to investigate the clinical advantage of bilateral TMS over unilateral TMS.

High dose Transcranial Magnetic Stimulation: High-dose TMS is a new method of brain stimulation proposed to rapidly improve depressive symptoms. High-dose TMS uses rapid repeated bursts of magnet pulses to stimulate the brain by delivering more pulses than usual over the same treatment time frame (e.g., 6000–6800 pulses per session rather than 3000 pulses) (Pan, et al., 2018). Studies are primarily in the form of case series ($n=7$) and case reports (Pan, et al., 2018; George, et al., 2014; Hadley, et al., 2011).

Multi-Locus Transcranial Magnetic Stimulation (mTMS): mTMS is an investigational form of TMS that is proposed to provide a means to administer tailored pulse sequences in which stimulus locations are electronically controlled and would allow selection of different stimulation targets without any physical movement of the transducer. mTMS may involve the use of 2–5 coils and an algorithm to enable the user to select a target location from within a region of the cortex, stimulate it in any desired direction and obtain adequate control over the target location without coil movement. Koponen et al. (2018) used an algorithm that yielded a set of five overlapping coils: two figure-of-eight coils at a 90° angle; a circular coil; and two four-leaf-clover coils at a 45° angle. mTMS is considered experimental for all indications. Clinical trials investigating mTMS are lacking.

Priming Transcranial Magnetic Stimulation (pTMS): Despite consistent and large treatment effects, the average reduction in depression scores with conventional rTMS has been reported as low as 37% with few patients meeting the criteria for response. Methods are being investigated for enhancing response rates to rTMS. A number of potential modalities have been suggested, including optimizing pulse number and intensity, increasing the treatment duration, selecting

appropriate patients, bilateral stimulation, and alternative treatment sites (e.g., parietal cortex, cerebellum) (Nongpiur, et al., 2011). Priming of the LF-rTMS (pTMS) has been proposed as an enhancing therapy and consists of “priming” the rTMS by delivering high-frequency rTMS (5 Hz-6Hz) before LF-rTMS (1 Hz), theoretically boosting LF-rTMS efficacy. There is a paucity of studies with small patient populations and short-term follow-up (Fitzgerald, et al., 2008; Nongpiur, et al., 2011; Iyer, et al., 2003).

Theta burst stimulation (TBS): TBS is a newer form of repetitive transcranial stimulation (rTMS) by which magnetic pulses are applied in bursts. The standard theta burst pattern consists of three bursts of pulses given at 50 Hz and repeated every 200 ms. TBS may be delivered as continuous (cTBS) or intermittent (iTBS) magnetic pulses and are intended to mimic endogenous theta rhythms of the brain. cTBS typically uses a 40 second train of uninterrupted TBS to the right dorsolateral prefrontal cortex and typically 600 pulses. Intermittent TBS (iTBS) sessions deliver two seconds of stimulation on the left dorsolateral prefrontal cortex followed by an 8 second pause (e.g., for a total of 190 seconds and typically 600 pulses). Studies in healthy participants have reported that the cTBS is inhibitory while the iTBS is excitatory. The effects of cTBS or iTBS are hypothesized to be due to the mimicking of long-term potentiation or long-term depression of synaptic transmission. TBS is proposed to exert longer lasting effects upon motor cortex excitability than conventional repetitive TMS and requires less stimulation time (e.g., 6 minutes per session vs. 30 to 40 minutes). TBS protocols have a potentially higher risk of triggering a seizure than traditional TMS protocols due to the high-frequency bursts (FDA, 2018; Abujadi, et al., 2018; Brunoni, et al., 2017; Guo, et al., 2017).

U.S. Food and Drug Administration (FDA): Brainsway Deep TMS System (with iTBS Protocol) (Brainsway Ltd., Jerusalem IL) is FDA 510(k) approved “for the treatment of depressive episodes in adult patients suffering from Major Depressive Disorder who failed to achieve satisfactory improvement from previous anti-depressant medication treatment in the current episode”. A deep TMS coil delivers pulses to the prefrontal cortex (FDA, 2025).

The Mag Vita TMS Therapy System w/Theta Burst Stimulation (Tonica, Elektroni A/S, Farnum, Denmark) is FDA 510(k) approved “for the treatment of major depressive disorder in adult patients who have failed to receive satisfactory improvement from prior antidepressant medication in the current episode”. The device uses a Cool-B70 figure 8 coil to deliver TBS to the left dorsolateral prefrontal cortex (L-DLPFC) using intermittent pulses (FDA, 2025). The Neurosoft TMS (Also called Cloud TMS) (TleEMG, LLC, Salem, NH) can be used to deliver continuous or intermittent theta-bursts TMS. Per the manufacturer the device is FDA approved for intermittent theta burst but not continuous (Cloud Neuro, 2018).

Literature Review: Studies investigating TBS for the treatment of major depressive disorder are lacking. TBS has been investigated for the treatment of other conditions including autism spectrum disorder, schizophrenia, spinal cord injury, complex regional pain syndrome (CRPS), neuropathic pain, epilepsy, tinnitus, Parkinson’s, and obsessive-compulsive disorder. Studies have primarily been in the form of pilot studies, case series and randomized controlled trials with small patient populations and short term-follow-ups (Naro, et al., 2019; Abujadi, et al., 2018; Koc, et al., 2017; Garg, et al., 2016; Oberman, et al., 2011). TMS devices are not FDA approved for the treatment of these other conditions.

Harika-Germaneau et al. (2019) conducted a six-week randomized, sham-controlled, double blind, parallel group trial (n=28, aged 18-65 years) comparing the effect of cTBS on obsessive-compulsive disorder (OCD) symptoms. Eligibility requirements included: DSM-IV-TR OCD diagnosed using the Mini-International Neuropsychiatric Interview (MINI), total Y-BOCS score of 20 or more, a total duration of the disease of at least two years and had received at least two 12-week adequate sequences and dose of treatment with SRIs but treatment resistant. Patients were excluded if they had: a diagnosis of schizophrenia; current major depressive disorder

(Montgomery Asberg Depression Rating Scale [MADRS] > 21); other psychotic disorders; bipolar I disorder; substance and alcohol dependence within the prior six months; suicidal (score ≥ 3 in MADRS, moderate or severe stage in MINI); metallic implant in the cranium (except teeth); severe or unstable medical conditions; history of TMS; history of epilepsy; neurological disorders leading to increased intracranial pressure; abnormal findings in brain MRI; and severe cardiac disorder and/or with intracardiac lines, cardiac pacemakers and other contraindication to MRI. Thirty rTMS sessions were delivered once a day, five days a week, for a total of six weeks. The cTBS treatment was administered with the MagPro® X100 with Option stimulator (MagVenture, Inc.) using the cool B-65 Active/Placebo (A/P) coil which could be configured in active or sham mode by flipping the coil over. cTBS stimulation consisted of three single biphasic pulses separated by 0.02 seconds (s) (50 Hz) repeated every 0.2 s (5 Hz) for a total of 600 pulses delivered in a 40 s session. Trained psychiatrists blind to the patient stimulation group completed clinical assessments including the Y-BOCS (primary outcome measure), Clinical Global Impression Severity (CGI-S), MADRS, the Brief Anxiety Scale (BAS), Global Assessment of Functioning (GAF), Brown Assessment of Belief Scale (BABS), and Hospital Anxiety and Depression scale (HAD). Patients were assessed at baseline, post-cTBS treatment (after six week of treatment), and at six-week follow-ups (12 weeks after baseline). No significant differences between the two groups were found with any of the outcome measures at any of the assessments. The only adverse event noted was a mild headache. Limitations of the study include: small patient population, lack of previous research and knowledge of cTMS for OCD, and heterogeneity of patient population as they were all on different types of medication regimens while in the trial. The conclusion of the clinical trial was that cTMS over the supplemental motor area had no clinically significant effect in treating OCD.

Oberman et al. (2011) conducted a systematic review of the literature to assess the safety of theta burst TMS. A total of 67 studies (n=1040) including 776 healthy control participants and 225 clinical patients met inclusion criteria. Diagnoses included: autism spectrum disorders (n=27), chronic pain (n=6), stroke (n=42), tinnitus (n=67), Parkinson's disease (n=37), dystonia (n=14), amyotrophic lateral sclerosis (ALS) (n=20), Fragile X (FX) (n=2) and multiple sclerosis (MS) (n=10). Areas of stimulation included: primary motor cortex (n=632); prefrontal cortex (n=235) supplementary motor area (SMA) (n=150); dorsal lateral prefrontal cortex (DLPFC) (n=97); frontal eye fields (FEF) (n=20); primary sensory cortex (n=98); other parietal loci (n=56); temporal cortex (n=67) including 46 to primary auditory cortex, 20 to inferior temporal cortex, and one to temporal-parietal junction; occipital cortex (n=102) and cerebellum (n=44). Multiple studies stimulated more than one site in separate sessions. Adverse events included: 1) one seizure in a healthy control subject during cTBS; 2) mild headaches; 3) nonspecific discomfort; 4) mild discomfort due to cutaneous sensation and neck muscle contractions; 5) worsening tinnitus; 6) nausea; 7) light headedness or vagal responses; and 8) unilateral eye pain and lacrimation. Limitations of the studies included: small, heterogeneous patient populations (n=1–50); heterogeneity of TBS protocols (e.g. cTBS, iTBS, other modified TBS protocols); no long-term follow-up; and lack of standardized methods for reporting adverse events. Due to the heterogeneity of the data, the safety of TBS could not be established. The authors recommended that future experiments proceed with caution and systematically document adverse events until more formal safety guidelines have been established.

Stanford Accelerated Intelligent Neuromodulation Therapy Protocol (SAINT): The SAINT protocol, also known as Stanford Neuromodulation Therapy (SNT), for administration of TMS is a novel form of iTBS delivered via an accelerated treatment schedule consisting of 50 sessions with 1800 pulses per session, 50-minute intersession interval, and delivered as 10 daily sessions over five consecutive days (Cole, et al., 2022; Cole, et al., 2020). This differs from traditional TMS protocols which are typically administered over the course a 4–6-week period with one treatment per day, for a total of 30–36 treatments. Six tapered treatments over the final three-week period may be included in the total 30-36 visits (Hutton, et al., 2023).

U.S. Food and Drug Administration (FDA): An example of an FDA cleared TMS device that utilizes the SAINT protocol is the Magnus Neuromodulation System (MNS) with SAINT Technology (Model Number 1001K) (Magnus Medical, Inc., Burlingame, CA). The FDA issued 510(k) clearance on September 1st, 2022 (FDA, 2025). The device is “indicated for the treatment of Major Depressive Disorder (MDD) in adult patients who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode.”

Literature Review: There is insufficient evidence in the peer reviewed literature evaluating the safety and efficacy of the SAINT protocol for the delivery of TMS for the treatment of TRD. Evidence is limited to two studies (i.e., RCT, open label without comparator) with short-term follow-ups and small patient populations conducted at the same institution (Cole, et al., 2022; Cole, et al., 2020).

The studies conducted by Cole and colleagues (Cole, et al., 2022; Cole, et al., 2020) were completed at the same institution and aimed to evaluate the safety and efficacy of the Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT) and Stanford Neuromodulation Therapy (SNT) protocols (i.e., 50 iTBS sessions consisting of 1800 pulses per session, 50-minute intersession interval, delivered as 10 daily sessions over five consecutive days at 90% resting motor threshold) for the treatment of treatment-resistant depression. The first of the two studies (n=21) had a prospective, open label design (Cole, et al., 2020) without a comparator. The second study (n=29) had a double-blind randomized controlled trial design (Cole, et al., 2022) that utilized sham accelerated iTBS as the comparator. The primary outcome measure in both studies was the change in depression severity assessed using the Montgomery-Asberg Depression Rating Scale (MADRS). Response and remission rates, safety, and tolerability were evaluated as secondary outcome measures. Follow-up occurred in the 2020 study at the end of each day’s 10 stimulation sessions and in the 2022 study at 4-weeks. Improvements in all outcome measures were reported by the authors in both studies however, the authors concluded in the RCT that “further trials are needed to determine SNT’s durability and to compare it with other treatments”. Limitations for both studies included the small sample sizes and short-term follow-up. Additional limitations for Cole, et al. (2020) included the open label design and lack of a comparator.

Systematic Review of All TMS Methods: Brunoni et al. (2017) conducted a systematic review and meta-analysis to establish a clinically meaningful hierarchy of efficacy and acceptability of the different rTMS modalities for the treatment of MDD. A total of 81 randomized clinical trials (RCTs) (n=4233) enrolling subjects with a primary diagnosis of an acute unipolar or bipolar depressive episode, including those that were not precluded due to comorbidities (e.g., anxiety or personality disorders), were analyzed. Included studies compared at least two of the following interventions:

- Low frequency (LF-rTMS) over the right dorsolateral prefrontal cortex (DLPFC)
- High frequency (HF-rTMS) over the left DLPFC
- Bilateral rTMS (LF over the right DLPFC and HF over the left DLPFC)
- Theta burst stimulation (TBS) including intermittent TBS over the left DLPFC, continuous over the right DLPFC or bilateral
- Priming TMS (pTMS) over the right DLPFC
- Accelerated TMS (aTMS) over the left DLPFC
- Synchronized TMS (sTMS) over the left DLPFC
- Deep TMS (dTMS) (H-Coil) over the left DLPFC
- Sham

Exclusion criteria were other study designs, trials performing less than 10 rTMS sessions, using frequencies between 2–4 Hz, or comparing only one modality of rTMS. The primary outcome measures were response rates and acceptability (dropout rate), and remission rates were a secondary outcome. Priming TMS, bilateral, HF-rTMS, TBS, and LF-rTMS were superior to sham for response and pTMS, bilateral, HF-TMS, and LF-TMS were superior to sham for remission. Bilateral rTMS appeared to be superior to sTMS. The estimated relative ranking of treatments implied that

pTMS and bilateral rTMS performed the best of all the interventions in terms of efficacy. However, findings were imprecise for most comparisons between active interventions, and no definite evidence of superiority could be supported for any particular intervention. Acceptability of all active interventions was similar to sham showing that they were well tolerated. pTMS was more acceptable (i.e., with smaller dropout rate) than HF-rTMS, LF-rTMS, sTMS, and sham. TBS was more effective than sham, but the authors noted that further clinical investigation is needed because the TBS sessions lasted approximately five minutes compared with thirty 30 minutes or longer for other strategies. Deep, synchronized, and accelerated TMS were not more effective than sham. Limitations of the studies include: small sample size (n=12–199); overall unclear to high risk of bias in the majority of the studies; lack of data on the different TMS approaches; and heterogeneity in treatment strategies. The authors concluded that clinical efficacy and acceptability between rTMS modalities could not be confirmed. High-quality RCTs are necessary to establish the efficacy of these modalities with a higher degree of credibility.

Diagnostic Navigated Transcranial Magnetic Stimulation (nTMS)

Navigated transcranial magnetic stimulation (nTMS) is being investigated as a noninvasive modality to map essential functional motor cortex areas for diagnostic indications and for preoperative treatment planning. It uses electromagnetic pulses to stimulate points of the patient's brain and then records the motor output (if any) on a standard electromyogram. Direct electrical stimulation (DES) is the gold standard for brain mapping and is used intraoperatively but is not used preoperatively. DES cannot be replaced by a noninvasive method due to its unique capability to stimulate subcortical structures accurately and to monitor function during surgery. Preoperative functional brain imaging is used widely in the context of rolandic (the motor area of the cerebral cortex lying just anterior to the central sulcus and comprising part of the precentral gyru) brain tumor surgeries. The most widely adopted method is functional magnetic resonance imaging (fMRI), but magnetoencephalography (MEG), PET, and electroencephalography have also been used for preoperative mapping (Takahashi, et al., 2013; Pitch, et al., 2012).

U.S. Food and Drug Administration (FDA)

In 2009, the Nexstim eXimia Navigated Brain Stimulation System (NexStim, North Attleboro, MA) received 510(k) FDA approval. The 510(k) summary indications for use state, "The Nexstim eXimia Navigated Brain Stimulation System (NBS System) is indicated for non-invasive mapping of the primary motor cortex of the brain to its cortical gyrus. The NBS System provides information that may be used in the assessment of the primary motor cortex for pre-procedural planning. The NBS System is not intended to be used during a surgical procedure. The NBS System is intended to be used by trained clinical professionals" (FDA, 2025).

Literature Review-navigated transcranial magnetic stimulation (nTMS)

There is limited evidence at this time to permit conclusions regarding the impact of nTMS testing on health outcomes. Several comparative studies with small sample sizes suggest that nTMS may be useful as a mapping modality of the motor cortex. Studies are primarily in the form of case series with small patient populations and lack a comparator. Additional well-designed clinical studies with larger patient populations are required (Krieg, et al., 2014; Krieg, et al., 2013; Coburger, et al., 2013; Tarapore, et al., 2012; Forster, et al., 2012; Krieg, et al., 2012; Picht, et al., 2012; Frey, et al., 2012; Makela, et al., 2012; Picht, et al., 2011).

Raffa et al. (2019) conducted a systematic review and meta-analysis of the current literature on the use of nTMS mapping and planning for surgery of motor-eloquent intrinsic brain tumors and to objectively evaluate and summarize the impact of the nTMS-based approach (occurrence of postoperative new permanent motor deficits, gross total resection [GTR] rate, size of craniotomy, length of surgery) as compared to standard surgery performed without using nTMS. Eight studies (n=1,233), including prospective observational controlled, prospective series, and retrospective series studies, met inclusion. Seven of the eight studies were included in analysis of the outcome

GTR rate, four in assessment of craniotomy size, and three for the length of surgery. Inclusion criteria included: studies that reported a comparison between patients operated using the nTMS motor mapping and planning vs. patients operated without using nTMS, and data on the occurrence of postoperative new permanent motor deficits, and on the GTR rate. Results between all eight studies suggested that there was a possibility of reducing the occurrence of postoperative new permanent motor deficits following nTMS. Seven of the studies reported a higher GTR rate using nTMS motor mapping, four reported a reduced size in craniotomy, and one reported longer duration of surgery using nTMS while two others reported shorter duration. Limitations of the analysis include: lack of well-conducted randomized control trials, heterogeneous patient populations, and limited data of effects on craniotomy size and length of surgery. The authors concluded that the meta-analysis demonstrated that nTMS motor mapping may be associated with a reduced risk of postoperative new permanent motor deficits and a higher probability to achieve a gross total resection of the tumor, but well-designed randomized control studies from multiple institutions are needed.

Hayes (2017; reviewed 2019) conducted a systematic review of the literature to evaluate nTMS for mapping of the primary motor cortex to provide information that may be used for presurgical planning for brain tumors. Seven studies met inclusion criteria including one retrospective review. Although the overall body of evidence suggested that nTMS may be beneficial, a definitive conclusion could not be made due to the poor quality of the evidence. Limitations of the studies included: small, heterogeneous patient populations; retrospective study design; lack of power analysis; difference in sample sizes between groups; short-term follow-ups; various follow-up durations; and limited statistical analyses. The 2019 review revealed no new studies on nTMS.

In a systematic review of observational studies, Takahashi et al. (2013) studied the spatial accuracy and clinical utility of nTMS in rolandic brain tumor surgery in or near the motor cortex. Eleven reports in which adult patients were examined with nTMS prior to surgery met the inclusion criteria. For mapping of the motor cortex, most studies used a biphasic TMS pulse (250–280 μ sec pulse length) from a figure-eight coil with an outer diameter of 70 mm applied at 110% of the resting motor threshold and a maximum frequency of 0.25 Hz.^{2–5,7–9,12,14–17,20,21} For lower-extremity stimulation the intensity was adapted on an individual basis. Quality criteria consisted of documentation of the influence of nTMS brain mapping on clinical decision making in a standardized prospective manner and/or performance of intraoperative direct electrical stimulation (DES) and comparison with nTMS results. Cross-observational assessment of nTMS accuracy was established by calculating a weighted mean distance between nTMS and DES. All studies reviewed concluded that nTMS correlated well with the “gold standard” of DES. The mean distance between motor cortex identified on nTMS and DES by using the mean distance in 81 patients described in six quantitatively evaluated studies was 6.18 mm. The nTMS results changed the surgical strategy based on anatomical imaging alone in 25.3% of all patients, based on the data obtained in 87 patients in two studies. The nTMS technique spatially correlates well with the gold standard of DES. Its functional information benefits surgical decision making and changes the treatment strategy in one-fourth of cases. The studies included in the review were limited by small sample sizes. The impact of nTMS on the operation was not reported in the majority of the studies.

In a 2016 search and summary report on nTMS, Hayes reported that although there was a moderate amount of published evidence, well-designed, large randomized controlled trials are lacking. A review of the abstracts showed conflicting findings. There was considerable overlap of authorship in the retrieved abstracts, and the majority of the published studies consisted of small patient populations with various diagnosis.

Professional Societies/Organizations

Professional society opinion on this technology is lacking.

Medicare Coverage Determinations

	Contractor	Determination Name/Number	Revision Effective Date
NCD		No Determination Found	
LCD	CGS Administrators, LLC	Repetitive Transcranial Magnetic Stimulation (rTMS) in Adults with Treatment Resistant Major Depressive Disorder (L36469)	1/6/2022
LCD	National Government Services, Inc.	Transcranial Magnetic Stimulation (L33398) (DL33398)	10/1/2020
LCD	Noridian Healthcare Solutions, LLC	Repetitive Transcranial Magnetic Stimulation (rTMS) in Adults with Treatment Resistant Major Depressive Disorder (L37086) (L37088)	12/1/2019
LCD	Palmetto GBA	Repetitive Transcranial Magnetic Stimulation (rTMS) in Adults with Treatment Resistant Major Depressive Disorder (L34869)	6/9/2022
LCD	Wisconsin Physicians Service Insurance Corporation	Transcranial Magnetic Stimulation (TMS) (L34641)	7/30/2020

Note: Please review the current Medicare Policy for the most up-to-date information.
(NCD = National Coverage Determination; LCD = Local Coverage Determination)

Coding Information

Notes:

1. This list of codes may not be all-inclusive since the American Medical Association (AMA) and Centers for Medicare & Medicaid Services (CMS) code updates may occur more frequently than policy updates.
2. Deleted codes and codes which are not effective at the time the service is rendered may not be eligible for reimbursement.

Considered Medically Necessary when criteria in the applicable policy statements listed above are met:

CPT®* Codes	Description
90867	Therapeutic repetitive transcranial magnetic stimulation (TMS) treatment; initial, including cortical mapping, motor threshold determination, delivery and management
90868	Therapeutic repetitive transcranial magnetic stimulation (TMS) treatment; subsequent delivery and management, per session
90869	Therapeutic repetitive transcranial magnetic stimulation (TMS) treatment; subsequent motor threshold re-determination with delivery and management

Considered Experimental/Investigational/Unproven:

CPT®* Codes	Description
-------------	-------------

0889T	Personalized target development for accelerated, repetitive high-dose functional connectivity MRI-guided theta-burst stimulation derived from a structural and resting-state functional MRI, including data preparation and transmission, generation of the target, motor threshold-starting location, neuronavigation files and target report, review and interpretation
0890T	Accelerated, repetitive high-dose functional connectivity MRI-guided theta-burst stimulation, including target assessment, initial motor threshold determination, neuronavigation, delivery and management, initial treatment day
0891T	Accelerated, repetitive high-dose functional connectivity MRI-guided theta-burst stimulation, including neuronavigation, delivery and management, subsequent treatment day
0892T	Accelerated, repetitive high-dose functional connectivity MRI-guided theta-burst stimulation, including neuronavigation, delivery and management, subsequent motor threshold redetermination with delivery and management, per treatment day

***Current Procedural Terminology (CPT®) ©2024 American Medical Association: Chicago, IL.**

References

1. Abujadi C, Croarkin PE, Bellini BB, Brentani H, Marcolin MA. Intermittent theta-burst transcranial magnetic stimulation for autism spectrum disorder: an open-label pilot study. *Braz J Psychiatry*. 2018 Jul-Sep;40(3):309-311.
2. Ahmed MA, Darwish ES, Khedr EM, El Serogy YM, Ali AM. Effects of low versus high frequencies of repetitive transcranial magnetic stimulation on cognitive function and cortical excitability in Alzheimer's dementia. *J Neurol*. 2012 Jan;259(1):83-92.
3. Aleman A, Sommer IE, Kahn RS. Efficacy of slow repetitive transcranial magnetic stimulation in the treatment of resistant auditory hallucinations in schizophrenia: a meta-analysis. *J Clin Psychiatry*. 2007 Mar;68(3):416-21.
4. Allan CL, Herrmann LL, Ebmeier KP. Transcranial magnetic stimulation in the management of mood disorders. *Neuropsychobiology*. 2011;64(3):163-9.
5. Allen CH, Kluger BM, Buard I. Safety of Transcranial Magnetic Stimulation in Children: A Systematic Review of the Literature. *Pediatr Neurol*. 2017 Mar;68:3-17.
6. American Psychological Association. Clinical practice guideline for the treatment of depression across three age cohorts. 2019. Accessed Jan 24, 2025. Available at URL address: <https://www.apa.org/depression-guideline/guideline.pdf>
7. American Psychiatric Association (APA) Practice Guidelines. Major depressive disorder. 2010. Accessed Jan 14, 2025. Available at URL address: <http://psychiatryonline.org/guidelines>
8. American Psychiatric Association (APA). Practice guideline for the treatment of patients with obsessive-compulsive disorder. Jul 2007. Accessed Jan 14, 2025. Available at URL address: <http://psychiatryonline.org/guidelines>
9. Anders M, Dvorakova J, Rathova L, Havrankova P, Pelcova P, Vaneckova M, et al. Efficacy of repetitive transcranial magnetic stimulation for the treatment of refractory chronic tinnitus: a randomized, placebo controlled study. *Neuro Endocrinol Lett*. 2010;31(2):238-49.

10. Arias P, Vivas J, Grieve KL, Cudeiro J. Double-blind, randomized, placebo controlled trial on the effect of 10 days low-frequency rTMS over the vertex on sleep in Parkinson's disease. *Sleep Med.* 2010 Sep;11(8):759-65.
11. Attal N, Poindessous-Jazat F, De Chauvigny E, Quesada C, Mhalla A, Ayache SS, Fermanian C, Nizard J, Peyron R, Lefaucheur JP, Bouhassira D. Repetitive transcranial magnetic stimulation for neuropathic pain: a randomized multicentre sham-controlled trial. *Brain.* 2021 Dec 16;144(11):3328-3339.
12. Avenanti A, Coccia M, Ladavas E, Provinciali L, Ceravolo MG. Low-frequency rTMS promotes use-dependent motor plasticity in chronic stroke: a randomized trial. *Neurology.* 2012 Jan 24;78(4):256-64.
13. Avery DH, Isenberg KE, Sampson SM, Janicak PG, Lisanby SH, Maixner DF, et al. Transcranial magnetic stimulation in the acute treatment of major depressive disorder: clinical response in an open-label extension trial. *J Clin Psychiatry.* 2008 Mar;69(3):441-51.
14. Awad BI, Carmody MA, Zhang X, Lin VW, Steinmetz MP. Transcranial Magnetic Stimulation After Spinal Cord Injury. *World Neurosurg.* 2013 Jan 12. pii: S1878-8750(13)00104-6.
15. Baeken C, Vanderhasselt MA, Remue J, Herremans S, Vanderbruggen N, Zeeuws D, Santermans L, De Raedt R. Intensive HF-rTMS treatment in refractory medication-resistant unipolar depressed patients. *J Affect Disord.* 2013 Nov;151(2):625-31.
16. Bais L, Vercammen A, Stewart R, van Es F, Visser B, Aleman A, Knegtering H. Short and long term effects of left and bilateral repetitive transcranial magnetic stimulation in schizophrenia patients with auditory verbal hallucinations: a randomized controlled trial. *PLoS One.* 2014 Oct 20;9(10):e108828.
17. Benadhira R, Thomas F, Bouaziz N, Braha S, Andrianisaina PS, Isaac C, Moulier V, Januel D. A randomized, sham-controlled study of maintenance rTMS for treatment-resistant depression (TRD). *Psychiatry Res.* 2017 Dec;258:226-233.
18. Benninger DH, Berman BD, Houdayer E, Pal N, Luckenbaugh DA, Schneider L, et al. Intermittent theta-burst transcranial magnetic stimulation for treatment of Parkinson disease. *Neurology.* 2011 Feb 15;76(7):601-9.
19. Berlim MT, Neufeld NH, Van den Eynde F. Repetitive transcranial magnetic stimulation (rTMS) for obsessive-compulsive disorder (OCD): an exploratory meta-analysis of randomized and sham-controlled trials. *J Psychiatr Res.* 2013c Aug;47(8):999-1006.
20. Berlim MT, Van den Eynde F. Repetitive transcranial magnetic stimulation over the dorsolateral prefrontal cortex for treating posttraumatic stress disorder: an exploratory meta-analysis of randomized, double-blind and sham-controlled trials. *Can J Psychiatry.* 2014 Sep;59(9):487-96.
21. Berlim MT, Van den Eynde F, Daskalakis ZJ. Efficacy and acceptability of high frequency repetitive transcranial magnetic stimulation (rTMS) versus electroconvulsive therapy (ECT) for major depression: a systematic review and meta-analysis of randomized trials. *Depress Anxiety.* 2013b Jul;30(7):614-23.

22. Bersani FS, Minichino A, Enticott PG, Mazzarini L, Khan N, Antonacci G, Raccach RN, Salviati M, Delle Chiaie R, Bersani G, Fitzgerald PB, Biondi M. Deep transcranial magnetic stimulation as a treatment for psychiatric disorders: a comprehensive review. *Eur Psychiatry*. 2013 Jan;28(1):30-9.
23. Bloch Y, Harel EV, Aviram S, Govezensky J, Ratzoni G, Levkovitz Y. Positive effects of repetitive transcranial magnetic stimulation on attention in ADHD Subjects: a randomized controlled pilot study. *World J Biol Psychiatry*. 2010 Aug;11(5):755-8.
24. Blumberger DM, Fitzgerald PB, Mulsant BH, Daskalakis ZJ. Repetitive transcranial magnetic stimulation for refractory symptoms in schizophrenia. *Curr Opin Psychiatry*. 2010 Mar;23(2):85-90.
25. Blumberger DM, Maller JJ, Thomson L, Mulsant BH, Rajji TK, Maher M, Brown PE, Downar J, Vila-Rodriguez F, Fitzgerald PB, Daskalakis ZJ. Unilateral and bilateral MRI-targeted repetitive transcranial magnetic stimulation for treatment-resistant depression: a randomized controlled study. *J Psychiatry Neurosci*. 2016 Jun;41(4):E58-66.
26. Boggio PS, Rocha M, Oliveira MO, Fecteau S, Cohen RB, Campanhã C, et al. Noninvasive brain stimulation with high-frequency and low-intensity repetitive transcranial magnetic stimulation treatment for posttraumatic stress disorder. *J Clin Psychiatry*. 2010 Aug;71(8):992-9.
27. Boldt I, Eriks-Hoogland I, Brinkhof MWG, de Bie R, Joggi D, von Elm E. Non-pharmacological interventions for chronic pain in people with spinal cord injury. *Cochrane Database of Systematic Reviews* 2014, Issue 11. Art. No.: CD009177. DOI: 10.1002/14651858.CD009177.pub2.
28. Borckardt JJ, Weinstein M, Reeves ST, Kozel FA, Nahas Z, Smith AR, et al. Postoperative left prefrontal repetitive transcranial magnetic stimulation reduces patient-controlled analgesia use. *Anesthesiology*. 2006 Sep;105(3):557-62.
29. Brainsway Ltd. Brainsway® announces positive final results of its deep-TMS multicenter study in obsessive compulsive disorder (OCD) patients. 2017. Accessed Jan 14, 2025. https://www.brainsway.com/news_events/brainsway-announces-positive-final-results-deep-tms-multicenter-study-obsessive-compulsive-disorder-ocd-patients/
30. Brighina F, Piazza A, Vitello G, Aloisio A, Palermo A, Daniele O, Fierro B. rTMS of the prefrontal cortex in the treatment of chronic migraine: a pilot study. *J Neurol Sci*. 2004 Dec 15;227(1):67-71
31. Brodbeck V, Thut G, Spinelli L, Romei V, Tyrand R, Michel CM, et al. Effects of repetitive transcranial magnetic stimulation on spike pattern and topography in patients with focal epilepsy. *Brain Topogr*. 2010 Jan;22(4):267-80.
32. Brown R, Cherian K, Jones K, Wickham R, Gomez R, Sahlem G. Repetitive transcranial magnetic stimulation for post-traumatic stress disorder in adults. *Cochrane Database of Systematic Reviews* 2024, Issue 8. Art. No.: CD015040.
33. Brunoni AR, Chaimani A, Moffa AH, Razza LB, Gattaz WF, Daskalakis Z, Carvalho AF. Repetitive Transcranial Magnetic Stimulation for the Acute Treatment of Major Depressive Episodes: A Systematic Review With Network Meta-analysis. *JAMA Psychiatry*. 2017 Feb 1;74(2):143-152.

34. Bulteau S, Beynel L, Marendaz C, et al. Twice-daily neuronavigated intermittent theta burst stimulation for bipolar depression: A Randomized Sham-Controlled Pilot Study. *Neurophysiol Clin*. 2019;49(5):371-375.
35. Cao P, Li Y, An B, Ye L, Xu Z. Efficacy and safety of repetitive transcranial magnetic stimulation combined with antidepressants in children and adolescents with depression: A systematic review and meta-analysis. *J Affect Disord*. 2023 Sep 1;336:25-34.
36. Carmi L, Tendler A, Bystritsky A, et al. Efficacy and Safety of Deep Transcranial Magnetic Stimulation for Obsessive-Compulsive Disorder: A Prospective Multicenter Randomized Double-Blind Placebo-Controlled Trial. *Am J Psychiatry*. 2019;176(11):931-938.
37. Carpenter LL, Janicak PG, Aaronson ST, Boyadjis T, Brock DG, Cook IA, et al. Transcranial magnetic stimulation (TMS) for major depression: a multisite, naturalistic, observational study of acute treatment outcomes in clinical practice. *Depress Anxiety*. 2012 Jul;29(7):587-96.
38. Centers for Medicare and Medicaid Services (CMS). Local Coverage Determinations (LCDs) alphabetical index. Accessed Jan 14, 2025. Available at URL address: <https://www.cms.gov/medicare-coverage-database/reports/local-coverage-proposed-lcds-alphabetical-report.aspx?proposedStatus=A&sortBy=title>
39. Centers for Medicare and Medicaid Services (CMS). National Coverage Determinations (NCDs) alphabetical index. Accessed Jan 14, 2025. Available at URL address: <https://www.cms.gov/medicare-coverage-database/reports/national-coverage-ncd-report.aspx?chapter=all&labOnly=allncd&sortBy=title>
40. Chang WH, Kim YH, Bang OY, Kim ST, Park YH, Lee PK. Long-term effects of rTMS on motor recovery in patients after subacute stroke. *J Rehabil Med*. 2010 Sep;42(8):758-64.
41. Chen JJ, Liu Z, Zhu D, Li Q, Zhang H, Huang H, Wei Y, Mu J, Yang D, Xie P. Bilateral vs. unilateral repetitive transcranial magnetic stimulation in treating major depression: a meta-analysis of randomized controlled trials. *Psychiatry Res*. 2014 Sep 30;219(1):51-7.
42. Chen R, Spencer DC, Weston J, Nolan SJ. Transcranial magnetic stimulation for the treatment of epilepsy. *Cochrane Database of Systematic Reviews* 2021, Issue 8. Art.No.:CD011025.
43. Chou YH, Hickey PT, Sundman M, Song AW, Chen NK. Effects of repetitive transcranial magnetic stimulation on motor symptoms in Parkinson disease: a systematic review and meta-analysis. *JAMA Neurol*. 2015 Apr;72(4):432-40.
44. Chung CL, Mak MK. Effect of Repetitive Transcranial Magnetic Stimulation on Physical Function and Motor Signs in Parkinson's Disease: A Systematic Review and Meta-Analysis. *Brain Stimul*. 2016 Jul-Aug;9(4):475-87.
45. Clarke BM, Upton AR, Kamath MV, Al-Harbi T, Castellanos CM. Transcranial magnetic stimulation for migraine: clinical effects. *J Headache Pain*. 2006 Oct;7(5):341-6.
46. Clinical TMS Society. Coverage guidance for transcranial magnetic stimulation (TMS) for major depressive disorder (MDD). 2021. Accessed Jan 24, 2025. Available at URL address: <https://clinicaltmsociety.org/wp-content/uploads/2024/08/CTMSS-Recommended-MDD-Coverage-Policy.pdf>

47. Coburger J, Musahl C, Henkes H, Horvath-Rizea D, Bittl M, Weissbach C, Hopf N. Comparison of navigated transcranial magnetic stimulation and functional magnetic resonance imaging for preoperative mapping in rolandic tumor surgery. *Neurosurg Rev*. 2013 Jan;36(1):65-75; discussion 75-6.
48. Cohen H, Kaplan Z, Kotler M, Kouperman I, Moisa R, Grisaru N. Repetitive transcranial magnetic stimulation of the right dorsolateral prefrontal cortex in posttraumatic stress disorder: a double-blind, placebo-controlled study. *Am J Psychiatry*. 2004 Mar;161(3):515-24.
49. Cole EJ, Phillips AL, Bentzley BS, Stimpson KH, Nejad R, Barmak F, Veerapal C, Khan N, Cherian K, Felber E, Brown R, Choi E, King S, Pankow H, Bishop JH, Azeez A, Coetzee J, Rapier R, Odenwald N, Carreon D, Hawkins J, Chang M, Keller J, Raj K, DeBattista C, Jo B, Espil FM, Schatzberg AF, Sudheimer KD, Williams NR. Stanford Neuromodulation Therapy (SNT): A Double-Blind Randomized Controlled Trial. *Am J Psychiatry*. 2022 Feb;179(2):132-141.
50. Cole EJ, Stimpson KH, Bentzley BS, Gulser M, Cherian K, Tischler C, Nejad R, Pankow H, Choi E, Aaron H, Espil FM, Pannu J, Xiao X, Duvio D, Solvason HB, Hawkins J, Guerra A, Jo B, Raj KS, Phillips AL, Barmak F, Bishop JH, Coetzee JP, DeBattista C, Keller J, Schatzberg AF, Sudheimer KD, Williams NR. Stanford Accelerated Intelligent Neuromodulation Therapy for Treatment-Resistant Depression. *Am J Psychiatry*. 2020 Aug 1;177(8):716-726.
51. Cordes J, Thünker J, Agelink MW, Arends M, Mobascher A, Wobrock T, et al. Effects of 10 Hz repetitive transcranial magnetic stimulation (rTMS) on clinical global impression in chronic schizophrenia. *Psychiatry Res*. 2010 May 15;177(1-2):32-6.
52. Corti M, Patten C, Triggs W. Repetitive transcranial magnetic stimulation of motor cortex after stroke: a focused review. *Am J Phys Med Rehabil*. 2012 Mar;91(3):254-70.
53. Cotelli M, Calabria M, Manenti R, Rosini S, Zanetti O, Cappa SF, et al. Improved language performance in Alzheimer disease following brain stimulation. *J Neurol Neurosurg Psychiatry*. 2011 Jul;82(7):794-7.
54. Croarkin PE, Elmaadawi AZ, Aaronson ST, Schrodtt GR Jr, Holbert RC, Verdoliva S, Heart KL, Demitrack MA, Strawn JR. Left prefrontal transcranial magnetic stimulation for treatment-resistant depression in adolescents: a double-blind, randomized, sham-controlled trial. *Neuropsychopharmacology*. 2021 Jan;46(2):462-469.
55. De Ridder D, Verstraeten E, Van der Kelen K, De Mulder G, Sunaert S, Verlooy J, et al. Transcranial magnetic stimulation for tinnitus: influence of tinnitus duration on stimulation parameter choice and maximal tinnitus suppression. *Otol Neurotol*. 2005 Jul;26(4):616-9.
56. Di Lazzaro V, Dileone M, Pilato F, Profice P, Cioni B, Meglio M, et al. Long-term motor cortex stimulation for amyotrophic lateral sclerosis. *Brain Stimul*. 2010 Jan;3(1):22-7.
57. Diefenbach GJ, Bragdon LB, Zertuche L, Hyatt CJ, Hallion LS, Tolin DF, Goethe JW, Assaf M2. Repetitive transcranial magnetic stimulation for generalised anxiety disorder: a pilot randomised, double-blind, sham-controlled trial. *Br J Psychiatry*. 2016 Sep;209(3):222-8.
58. Dionísio A, Duarte IC, Patrício M, Castelo-Branco M. The Use of Repetitive Transcranial Magnetic Stimulation for Stroke Rehabilitation: A Systematic Review. *J Stroke Cerebrovasc Dis*. 2018 Jan;27(1):1-31.

59. Dlabac-de Lange JJ, Knegtering R, Aleman A. Repetitive transcranial magnetic stimulation for negative symptoms of schizophrenia: review and meta-analysis. *J Clin Psychiatry*. 2010 Apr;71(4):411-8.
60. Dobson KS, Hollon SD, Dimidjian S, Schmalting KB, Kohlenberg RJ, Gallop RJ, Rizvi SL, Gollan JK, Dunner DL, Jacobson NS. Randomized trial of behavioral activation, cognitive therapy, and antidepressant medication in the prevention of relapse and recurrence in major depression. *J Consult Clin Psychol*. 2008 Jun;76(3):468-77.
61. Dos Santos RBC, Galvão SCB, Frederico LMP, et al. Cortical and spinal excitability changes after repetitive transcranial magnetic stimulation combined to physiotherapy in stroke spastic patients. *Neurol Sci*. 2019;40(6):1199-1207.
62. Dougall N, Maayan N, Soares-Weiser K, McDermott LM, McIntosh A. Transcranial magnetic stimulation (TMS) for schizophrenia. *Cochrane Database of Systematic Reviews* 2015, Issue 8. Art. No.: CD006081.
63. Du J, Yang F, Liu L, Hu J, Cai B, Liu W, Xu G, Liu X. Repetitive transcranial magnetic stimulation for rehabilitation of poststroke dysphagia: A randomized, double-blind clinical trial. *Clin Neurophysiol*. 2016 Mar;127(3):1907-13.
64. Dunner DL, Aaronson ST, Sackeim HA, Janicak PG, Carpenter LL, Boyadjis T, et al. A multisite, naturalistic, observational study of transcranial magnetic stimulation for patients with pharmacoresistant major depressive disorder: durability of benefit over a 1-year follow-up period. *J Clin Psychiatry*. 2014 Sep 16.
65. Elbeh KAM, Elserogy YMB, Khalifa HE, Ahmed MA, Hafez MH, Khedr EM. Repetitive transcranial magnetic stimulation in the treatment of obsessive-compulsive disorders: Double blind randomized clinical trial. *Psychiatry Res*. 2016 Apr 30;238:264-269.
66. Emara TH, Moustafa RR, Elnahas NM, Elganzoury AM, Abdo TA, Mohamed SA, et al. Repetitive transcranial magnetic stimulation at 1Hz and 5Hz produces sustained improvement in motor function and disability after ischaemic stroke. *Eur J Neurol*. 2010 Sep;17(9):1203-9. Epub 2010 Apr 8.
67. Eranti S, Mogg A, Pluck G, Landau S, Purvis R, Brown RG, et al. A randomized, controlled trial with 6-month follow-up of repetitive transcranial magnetic stimulation and electroconvulsive therapy for severe depression. *Am J Psychiatry*. 2007 Jan;164(1):73-81.
68. Fang J, Zhou M, Yang M, Zhu C, He L. Repetitive transcranial magnetic stimulation for the treatment of amyotrophic lateral sclerosis or motor neuron disease. *Cochrane Database of Systematic Reviews* 2013, Issue 5. Art. No.: CD008554.
69. Feffer K, Lapidus KAB, Braw Y, Bloch Y, Kron S, Netzer R, Nitzan U. Factors associated with response after deep transcranial magnetic stimulation in a real-world clinical setting: Results from the first 40 cases of treatment-resistant depression. *Eur Psychiatry*. 2017 Jul;44:61-67.
70. Feifel D, Pappas K. Treating Clinical Depression with Repetitive Deep Transcranial Magnetic Stimulation Using the Brainsway H1-coil. *J Vis Exp*. 2016 Oct 4;(116).
71. Ferreira NR, Junqueira YN, Corrêa NB, et al. The efficacy of transcranial direct current stimulation and transcranial magnetic stimulation for chronic orofacial pain: A systematic review. *PLoS One*. 2019;14(8):e0221110. Published 2019 Aug 15.

72. Ferrulli A, Macrì C, Terruzzi I, et al. Weight loss induced by deep transcranial magnetic stimulation in obesity: A randomized, double-blind, sham-controlled study. *Diabetes Obes Metab.* 2019;21(8):1849-1860.
73. Filipović SR, Rothwell JC, Bhatia K. Slow (1 Hz) repetitive transcranial magnetic stimulation (rTMS) induces a sustained change in cortical excitability in patients with Parkinson's disease. *Clin Neurophysiol.* 2010 Jul;121(7):1129-37.
74. Fitzgerald PB, Benitez J, Daskalakis JZ, Brown TL, Marston NA, de Castella A, et al. A double-blind sham-controlled trial of repetitive transcranial magnetic stimulation in the treatment of refractory auditory hallucinations. *J Clin Psychopharmacol.* 2005 Aug;25(4):358-62.
75. Fitzgerald PB, Benitez J, de Castella A, Daskalakis ZJ, Brown TL, Kulkarni J. A randomized, controlled trial of sequential bilateral repetitive transcranial magnetic stimulation for treatment-resistant depression. *Am J Psychiatry.* 2006a Jan;163(1):88-94.
76. Fitzgerald PB, Grace N, Hoy KE, Bailey M, Daskalakis ZJ. An open label trial of clustered maintenance rTMS for patients with refractory depression. *Brain Stimul.* 2013 May;6(3):292-7.
77. Fitzgerald PB, Hoy KE, Elliot D, Susan McQueen RN, Wambeek LE, Daskalakis ZJ. Accelerated repetitive transcranial magnetic stimulation in the treatment of depression. *Neuropsychopharmacology.* 2018 Jun;43(7):1565-1572.
78. Fitzgerald PB, Hoy K, McQueen S, Segrave R, Been G, Kulkarni J, Daskalakis ZJ. I: Priming stimulation enhances the effectiveness of low-frequency, right prefrontal cortex transcranial magnetic stimulation in major depression. *J Clin Psychopharmacol* 2008; 28:52–58.
79. Fitzgerald PB, Hoy KE, Singh A, Gunewardene R, Slack C, Ibrahim S, Hall PJ, Daskalakis ZJ. Equivalent beneficial effects of unilateral and bilateral prefrontal cortex transcranial magnetic stimulation in a large randomized trial in treatment-resistant major depression. *Int J Neuropsychopharmacol.* 2013b Oct;16(9):1975-84.
80. Folmer RL, Theodoroff SM, Casiana L, Shi Y, Griest S, Vachhani J. Repetitive Transcranial Magnetic Stimulation Treatment for Chronic Tinnitus: A Randomized Clinical Trial. *JAMA Otolaryngol Head Neck Surg.* 2015 Aug;141(8):716-22.
81. Forster MT, Senft C, Hattingen E, Lorei M, Seifert V, Szelényi A. Motor cortex evaluation by nTMS after surgery of central region tumors: a feasibility study. *Acta Neurochir (Wien).* 2012 Aug;154(8):1351-9.
82. Frank G, Kleinjung T, Landgrebe M, Vielsmeier V, Steffenhagen C, Burger J, et al. Left temporal low-frequency rTMS for the treatment of tinnitus: clinical predictors of treatment outcome--a retrospective study. *Eur J Neurol.* 2010 Jul;17(7):951-6.
83. Fregni F, Boggio PS, Valle AC, Rocha RR, Duarte J, Ferreira MJ, et al. A sham-controlled trial of a 5-day course of repetitive transcranial magnetic stimulation of the unaffected hemisphere in stroke patients. *Stroke.* 2006 Aug;37(8):2115-22.
84. Fregni F, Santos CM, Myczkowski ML, Rigolino R, Gallucci-Neto J, Barbosa ER, et al. Repetitive transcranial magnetic stimulation is as effective as fluoxetine in the treatment of

depression in patients with Parkinson's disease. *J Neurol Neurosurg Psychiatry*. 2004 Aug;75(8):1171-4.

85. Freitas C, Fregni F, Pascual-Leone A. Meta-analysis of the effects of repetitive transcranial magnetic stimulation (rTMS) on negative and positive symptoms in schizophrenia. *Schizophr Res*. 2009 Mar;108(1-3):11-24.
86. Freitas C, Pearlman C, Pascual-Leone A. Treatment of auditory verbal hallucinations with transcranial magnetic stimulation in a patient with psychotic major depression: one-year follow-up. *Neurocase*. 2012 Feb;18(1):57-65.
87. Frey D, Strack V, Wiener E, Jussen D, Vajkoczy P, Picht T. A new approach for corticospinal tract reconstruction based on navigated transcranial stimulation and standardized fractional anisotropy values. *Neuroimage*. 2012 Sep;62(3):1600-9.
88. Galal S, Ismail N, Niel G. A Systematic Review and Meta-analysis of Randomized Controlled Trials on the Effect of Transcranial Magnetic Stimulation on Tinnitus Management. *Cent Asian J Glob Health*. 2020 Mar 31;9(1):e356.
89. Galhardoni R, Correia GS, Araujo H, Yeng LT, Fernandes DT, Kaziyama HH, Marcolin MA, Bouhassira D, Teixeira MJ, de Andrade DC. Repetitive transcranial magnetic stimulation in chronic pain: a review of the literature. *Arch Phys Med Rehabil*. 2015 Apr;96(4 Suppl):S156-72.
90. Galletly CA, Carnell BL, Clarke P, Gill S. A Comparison of Right Unilateral and Sequential Bilateral Repetitive Transcranial Magnetic Stimulation for Major Depression: A Naturalistic Clinical Australian Study. *J ECT*. 2017 Mar;33(1):58-62.
91. Garg S, Sinha VK, Tikka SK, Mishra P, Goyal N. The efficacy of cerebellar vermal deep high frequency (theta range) repetitive transcranial magnetic stimulation (rTMS) in schizophrenia: A randomized rater blind-sham controlled study. *Psychiatry Res*. 2016 Sep 30;243:413-20.
92. Gaynes BN, Lloyd SW, Lux L, Gartlehner G, Hansen RA, Brode S, et al. Repetitive transcranial magnetic stimulation for treatment-resistant depression: a systematic review and meta-analysis. *J Clin Psychiatry*. 2014 May;75(5):477-89; quiz 489.
93. Gaynes BN, Lux L, Lloyd S, Hansen RA, Gartlehner G, Thieda P, et al. Nonpharmacologic Interventions for Treatment-Resistant Depression in Adults. Comparative Effectiveness Review No. 33. (Prepared by RTI International-University of North Carolina [RTI-UNC] Evidence-Based Practice Center under Contract No. 290-02-0016I.) AHRQ Publication No. 11-EHC056-EF. Rockville, MD: Agency for Healthcare Research and Quality. September 23, 2011.
94. George MS, Lisanby SH, Avery D, McDonald WM, Durkalski V, Pavlicova M, et al. Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder: a sham-controlled randomized trial. *Arch Gen Psychiatry*. 2010 May;67(5):507-16.
95. George MS, Raman R, Benedek DM, Pelic CG, Grammer GG, Stokes KT, Schmidt M, Spiegel C, Dealmeida N, Beaver KL, Borckardt JJ, Sun X, Jain S, Stein MB. A two-site pilot randomized 3 day trial of high dose left prefrontal repetitive transcranial magnetic stimulation (rTMS) for suicidal inpatients. *Brain Stimul*. 2014 May-Jun;7(3):421-31.

96. Gili M, Vicens C, Roca M, Andersen P, McMillan D. Interventions for preventing relapse or recurrence of depression in primary health care settings: A systematic review. *Prev Med.* 2015 Jul;76 Suppl:S16-21.
97. Graef P, Dadalt MLR, Rodríguez DAMDS, Stein C, Pagnussat AS. Transcranial magnetic stimulation combined with upper-limb training for improving function after stroke: A systematic review and meta-analysis. *J Neurol Sci.* 2016 Oct 15;369:149-158.
98. Grall-Bronnec M, Sauvaget A. The use of repetitive transcranial magnetic stimulation for modulating craving and addictive behaviours: a critical literature review of efficacy, technical and methodological considerations. *Neurosci Biobehav Rev.* 2014 Nov;47:592-613.
99. Guo Q, Li C, Wang J. Updated Review on the Clinical Use of Repetitive Transcranial Magnetic Stimulation in Psychiatric Disorders. *Neurosci Bull.* 2017 Dec;33(6):747-756.
100. Hadley D, Anderson BS, Borckardt JJ, Arana A, Li X, Nahas Z, et al. Safety, tolerability, and effectiveness of high doses of adjunctive daily left prefrontal repetitive transcranial magnetic stimulation for treatment-resistant depression in a clinical setting. *J ECT.* 2011 Mar;27(1):18-25.
101. Hansen PE, Ravnkilde B, Videbech P, Clemmensen K, Sturlason R, Reiner M, et al. Low-frequency repetitive transcranial magnetic stimulation inferior to electroconvulsive therapy in treating depression. *J ECT.* 2011 Mar;27(1):26-32.
102. Harika-Germaneau G, Rachid F, Chatard A, et al. Continuous theta burst stimulation over the supplementary motor area in refractory obsessive-compulsive disorder treatment: A randomized sham-controlled trial. *Brain Stimul.* 2019;12(6):1565-1571.
103. Hartelius L, Svantesson P, Hedlund A, Holmberg B, Revesz D, Thorlin T. Short-term effects of repetitive transcranial magnetic stimulation on speech and voice in individuals with Parkinson's disease. *Folia Phoniatr Logop.* 2010;62(3):104-9.
104. Hayes, Inc. Directory Report. High frequency left repetitive transcranial magnetic stimulation for treatment-resistant major depressive disorder. Hayes, Inc.; 2016, Nov.
105. Hayes, Inc. Directory Report. Comparative effectiveness review of high-frequency left repetitive transcranial magnetic stimulation versus other neurostimulation approaches to treatment-resistant depression. Hayes, Inc.; 2016, Dec.
106. Hayes, Inc. Directory Report. Transcranial magnetic stimulation (TMS) to enhance pharmacotherapy for depression. Hayes, Inc.; 2014 Mar 19.
107. Hayes, Inc. Prognosis overview. Cerana single-pulse transcranial magnetic stimulator. Hayes, Inc.; 2014 Oct.
108. Hayes Inc. Prognosis overview. NeuroAD therapy system for Alzheimer disease. Hayes, Inc.; Mar 2018.
109. Hayes, Inc. Search and summary. Single-Pulse Transcranial Magnetic Stimulation Using SpringTMS (eNeura Inc.) for Treatment of Acute Migraines. Hayes, Inc.; Feb 22, 2018.
110. Hayes, Inc. Technology Brief. Low frequency right repetitive transcranial magnetic stimulation for treatment-resistant major depressive disorder. Hayes, Inc.; 2016, Sept.

111. Hayes, Inc. Technology Brief. The clinical utility of navigated transcranial magnetic stimulation for presurgical planning for brain tumors. Hayes, Inc.; May 18, 2017.
112. He H, Lu J, Yang L, Zheng J, Gao F, Zhai Y, Feng J, Fan Y, Ma X. Repetitive transcranial magnetic stimulation for treating the symptoms of schizophrenia: A PRISMA compliant meta-analysis. *Clin Neurophysiol*. 2017 May;128(5):716-724.
113. He Y, Li K, Chen Q, Yin J, Bai D. Repetitive Transcranial Magnetic Stimulation on Motor Recovery for Patients With Stroke: A PRISMA Compliant Systematic Review and Meta-analysis. *Am J Phys Med Rehabil*. 2020;99(2):99-108.
114. Henkin RI, Potolicchio SJ Jr, Levy LM. Improvement in smell and taste dysfunction after repetitive transcranial magnetic stimulation. *Am J Otolaryngol*. 2011 Jan-Feb;32(1):38-46.
115. Herwig U, Fallgatter AJ, Höppner J, Eschweiler GW, Kron M, Hajak G, et al. Antidepressant effects of augmentative transcranial magnetic stimulation: randomised multicentre trial. *Br J Psychiatry*. 2007 Nov;191:441-8.
116. Hodaj H, Alibeu JP, Payen JF, Lefaucheur JP. Treatment of chronic facial pain including cluster headache by repetitive transcranial magnetic stimulation of the motor cortex with maintenance sessions: a naturalistic study. *Brain Stimul*. 2015 Jul-Aug;8(4):801-7.
117. Hoffman RE, Hawkins KA, Guorguieva R, Boutros NN, Rachid F, Carroll K et al. Transcranial magnetic stimulation of left temporoparietal cortex and medication-resistant auditory hallucinations. *Arch Gen Psychiatry*. 2003 Jan;60:49-56.
118. Hutton TM, Aaronson ST, Carpenter LL, Pages K, Krantz D, Lucas L, Chen B, Sackeim HA. Dosing transcranial magnetic stimulation in major depressive disorder: Relations between number of treatment sessions and effectiveness in a large patient registry. *Brain Stimul*. 2023 Sep-Oct;16(5):1510-1521.
119. Institute for Clinical Systems Improvement. Depression, Adult in primary care. 17th Edition. Mar 2016. Accessed Jan 19, 2024. Available at: https://www.icsi.org/guidelines__more/catalog_guidelines_and_more/catalog_guidelines/catalog_behavioral_health_guidelines/depression/
120. Isserles M, Rosenberg O, Dannon P, Levkovitz Y, Kotler M, Deutsch F, Lerer B, Zangen A. Cognitive-emotional reactivation during deep transcranial magnetic stimulation over the prefrontal cortex of depressive patients affects antidepressant outcome. *J Affect Disord*. 2011 Feb;128(3):235-42.
121. Iyer MB, Schleper N, Wassermann EM. Priming stimulation enhances the depressant effect of low-frequency repetitive transcranial magnetic stimulation. *J Neurosci*. 2003 Nov 26;23(34):10867-72.
122. Jang S, Jung S, Pae C, Kimberly BP, Craig Nelson J, Patkar AA. Predictors of relapse in patients with major depressive disorder in a 52-week, fixed dose, double blind, randomized trial of selegiline transdermal system (STS). *J Affect Disord*. 2013 Dec;151(3):854-9.
123. Janicak PG, Nahas Z, Lisanby SH, Solvason HB, Sampson SM, McDonald WM, et al. Durability of clinical benefit with transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant major depression: assessment of relapse during a 6-month, multisite, open-label study. *Brain Stimul*. 2010 Oct;3(4):187-99.

124. Jin Y, Xing G, Li G, Wang A, Feng S, Tang Q, Liao X, Guo Z, McClure MA, Mu Q. High Frequency Repetitive Transcranial Magnetic Stimulation Therapy For Chronic Neuropathic Pain: A Meta-analysis. *Pain Physician*. 2015 Nov;18(6):E1029-46.
125. Karsen EF, Watts BV, Holtzheimer PE. Review of the effectiveness of transcranial magnetic stimulation for post-traumatic stress disorder. *Brain Stimul*. 2014 Mar-Apr;7(2):151-7.
126. Kedzior KK, Gellersen HM, Brachetti AK, Berlim MT. Deep transcranial magnetic stimulation (DTMS) in the treatment of major depression: An exploratory systematic review and meta-analysis. *J Affect Disord*. 2015 Nov 15;187:73-83.
127. Kedzior KK, Reitz SK, Azorina V, Loo C. Durability of the antidepressant effect of the high-frequency repetitive transcranial magnetic stimulation (rTMS) In the absence of maintenance treatment in major depression: a systematic review and meta-analysis of 16 double-blind, randomized, sham-controlled trials. *Depress Anxiety*. 2015 Mar;32(3):193-203.
128. Keshtkar M, Ghanizadeh A, Firoozabadi A. Repetitive transcranial magnetic stimulation versus electroconvulsive therapy for the treatment of major depressive disorder, a randomized controlled clinical trial. *J ECT*. 2011 Dec;27(4):310-4.
129. Khaleel SH, Bayoumy IM, El-Nabil LM, Moustafa RR. Differential hemodynamic response to repetitive transcranial magnetic stimulation in acute stroke patients with cortical versus subcortical infarcts. *Eur Neurol*. 2010;63(6):337-42.
130. Khedr EM, Ahmed MA, Fathy N, Rothwell JC. Therapeutic trial of repetitive transcranial magnetic stimulation after acute ischemic stroke. *Neurology*. 2005 Aug 9;65(3):466-8.
131. Khedr EM, Al Fawal B, Abdelwarith A, Saber M, Rothwell JC. Repetitive transcranial magnetic stimulation for treatment of tardive syndromes: double randomized clinical trial. *J Neural Transm (Vienna)*. 2019;126(2):183-191.
132. Khedr EM, Rothwell JC, Ahmed MA, El-Atar A. Effect of daily repetitive transcranial magnetic stimulation for treatment of tinnitus: comparison of different stimulus frequencies. *J Neurol Neurosurg Psychiatry*. 2008 Feb;79(2):212-5.
133. Khedr EM, Abo-Elfetoh N, Rothwell JC. Treatment of post-stroke dysphagia with repetitive transcranial magnetic stimulation. *Acta Neurol Scand*. 2009 Mar;119(3):155-61.
134. Kim BR, Kim DY, Chun MH, Yi JH, Kwon JS. Effect of repetitive transcranial magnetic stimulation on cognition and mood in stroke patients: a double-blind, sham-controlled trial. *Am J Phys Med Rehabil*. 2010 May;89(5):362-8.
135. Kim JK, Park HS, Bae JS, Jeong YS, Jung KJ, Lim JY. Effects of multi-session intermittent theta burst stimulation on central neuropathic pain: A randomized controlled trial. *NeuroRehabilitation*. 2020;46(1):127-134.
136. Kleinjung T, Eichhammer P, Langguth B, Jacob P, Marienhagen J, Hajak G, et al. Long-term effects of repetitive transcranial magnetic stimulation (rTMS) in patients with chronic tinnitus. *Otolaryngol Head Neck Surg*. 2005 Apr;132(4):566-9.

137. Knijnik LM, Dussán-Sarria JA, Rozisky JR, Torres IL, Brunoni AR, Fregni F, Caumo W. Repetitive Transcranial Magnetic Stimulation for Fibromyalgia: Systematic Review and Meta-Analysis. *Pain Pract.* 2016 Mar;16(3):294-304.
138. Koc G, Gokcil Z, Bek S, Kasikci T, Eroglu E, Odabasi Z. Effects of continuous theta burst transcranial magnetic stimulation on cortical excitability in patients with idiopathic generalized epilepsy. *Epilepsy Behav.* 2017 Dec;77:26-29.
139. Koponen LM, Nieminen JO, Ilmoniemi RJ. Multi-locus transcranial magnetic stimulation-theory and implementation. *Brain Stimul.* 2018 Jul - Aug;11(4):849-855.
140. Korzhova J, Bakulin I, Sinitsyn D, et al. High-frequency repetitive transcranial magnetic stimulation and intermittent theta-burst stimulation for spasticity management in secondary progressive multiple sclerosis. *Eur J Neurol.* 2019;26(4):680-e44.
141. Kranz G, Shamim EA, Lin PT, Kranz GS, Hallett M. Transcranial magnetic brain stimulation modulates blepharospasm: a randomized controlled study. *Neurology.* 2010 Oct 19;75(16):1465-71.
142. Krieg SM, Shiban E, Buchmann N, Gempt J, Foerschler A, Meyer B, Ringel F. Utility of presurgical navigated transcranial magnetic brain stimulation for the resection of tumors in eloquent motor areas. *J Neurosurg.* 2012 May;116(5):994-1001.
143. Krieg SM, Shiban E, Buchmann N, Meyer B, Ringel F. Presurgical navigated transcranial magnetic brain stimulation for recurrent gliomas in motor eloquent areas. *Clin Neurophysiol.* 2013 Mar;124(3):522-7.
144. Krieg SM, Sabih J, Bulubasova L, Obermueller T, Negwer C, Janssen I, Shiban E, Meyer B, Ringel F. Preoperative motor mapping by navigated transcranial magnetic brain stimulation improves outcome for motor eloquent lesions. *Neuro Oncol.* 2014 Sep;16(9):1274-82.
145. Kumar N, Vishnubhatla S, Wadhawan AN, Minhas S, Gupta P. A randomized, double blind, sham-controlled trial of repetitive transcranial magnetic stimulation (rTMS) in the treatment of negative symptoms in schizophrenia. *Brain Stimul.* 2020;13(3):840-849.
146. Kumru H, Murillo N, Samso JV, Valls-Sole J, Edwards D, Pelayo R, et al. Reduction of spasticity with repetitive transcranial magnetic stimulation in patients with spinal cord injury. *Neurorehabil Neural Repair.* 2010 Jun;24(5):435-41.
147. Kwon HJ, Lim WS, Lim MH, Lee SJ, Hyun JK, Chae JH, et al. 1-Hz low frequency repetitive transcranial magnetic stimulation in children with Tourette's syndrome. *Neurosci Lett.* 2011 Mar 29;492(1):1-4.
148. Lam RW, Chan P, Wilkins-Ho M, Yatham LN. Repetitive transcranial magnetic stimulation for treatment-resistant depression: a systematic review and metaanalysis. *Can J Psychiatry.* 2008 Sep;53(9):621-31.
149. Lan L, Zhang X, Li X, Rong X, Peng Y. The efficacy of transcranial magnetic stimulation on migraine: a meta-analysis of randomized controlled trails. *J Headache Pain.* 2017 Aug 22;18(1):86. doi: 10.1186/s10194-017-0792-4.
150. Landeros-Weisenberger A, Mantovani A, Motlagh MG, de Alvarenga PG, Katsoyich L, Leckman JF, Lisanby SH. Randomized Sham Controlled Double-blind Trial of Repetitive

Transcranial Magnetic Stimulation for Adults With Severe Tourette Syndrome. *Brain Stimul.* 2015 May-Jun;8(3):574-81. doi: 10.1016/j.brs.2014.11.015.

151. Landgrebe M, Binder H, Koller M, Eberl Y, Kleinjung T, Eichhammer P, et al. Design of a placebo-controlled, randomized study of the efficacy of repetitive transcranial magnetic stimulation for the treatment of chronic tinnitus. *BMC Psychiatry.* 2008 Apr 15;8:23.
152. Levkovitz Y, Harel EV, Roth Y, Braw Y, Most D, Katz LN, Sheer A, Gersner R, Zangen A. Deep transcranial magnetic stimulation over the prefrontal cortex: evaluation of antidepressant and cognitive effects in depressive patients. *Brain Stimul.* 2009 Oct;2(4):188-200.
153. Levkovitz Y, Isserles M, Padberg F, Lisanby SH, Bystritsky A, Xia G, Tendler A, Daskalakis ZJ, Winston JL, Dannon P, Hafez HM, Reti IM, Morales OG, Schlaepfer TE, Hollander E, Berman JA, Husain MM, Sofer U, Stein A, Adler S, Deutsch L, Deutsch F, Roth Y, George MS, Zangen A. Efficacy and safety of deep transcranial magnetic stimulation for major depression: a prospective multicenter randomized controlled trial. *World Psychiatry.* 2015 Feb;14(1):64-73.
154. Levkovitz Y, Roth Y, Harel EV, Braw Y, Sheer A, Zangen A. A randomized controlled feasibility and safety study of deep transcranial magnetic stimulation. *Clin Neurophysiol.* 2007 Dec;118(12):2730-44.
155. Li H, Wang J, Li C, Xiao Z. Repetitive transcranial magnetic stimulation (rTMS) for panic disorder in adults. *Cochrane Database of Systematic Reviews* 2014, Issue 9. Art. No.: CD009083.
156. Li J, Cao X, Liu S, Li X, Xu Y. Efficacy of repetitive transcranial magnetic stimulation on auditory hallucinations in schizophrenia: A meta-analysis. *Psychiatry Res.* 2020;290:113141.
157. Li S, Jiao R, Zhou X, Chen S. Motor recovery and antidepressant effects of repetitive transcranial magnetic stimulation on Parkinson disease: A PRISMA-compliant meta-analysis. *Medicine (Baltimore).* 2020b;99(18):e19642.
158. Li Y, Qu Y, Yuan M, Du T. Low-frequency repetitive transcranial magnetic stimulation for patients with aphasia after stroke: A meta-analysis. *J Rehabil Med.* 2015 Sep;47(8):675-81.
159. Liao X, Li G, Wang A, Liu T, Feng S, Guo Z, Tang Q, Jin Y, Xing G, McClure MA, Chen H, He B, Liu H, Mu Q. Repetitive Transcranial Magnetic Stimulation as an Alternative Therapy for Cognitive Impairment in Alzheimer's Disease: A Meta-Analysis. *J Alzheimers Dis.* 2015;48(2):463-72.
160. Lim JY, Kang EK, Paik NJ. Repetitive transcranial magnetic stimulation to hemispatial neglect in patients after stroke: an open-label pilot study. *J Rehabil Med.* 2010 May;42(5):447-52.
161. Lin Y, Jiang WJ, Shan PY, et al. The role of repetitive transcranial magnetic stimulation (rTMS) in the treatment of cognitive impairment in patients with Alzheimer's disease: A systematic review and meta-analysis. *J Neurol Sci.* 2019;398:184-191.
162. Lipton RB, Dodick DW, Silberstein SD, Saper JR, Aurora SK, Pearlman SH, et al. Single-pulse transcranial magnetic stimulation for acute treatment of migraine with aura: a

randomised, double-blind, parallel-group, sham-controlled trial. *Lancet Neurol*. 2010 Apr;9(4):373-80.

163. Liu B, Zhang Y, Zhang L, Li L. Repetitive transcranial magnetic stimulation as an augmentative strategy for treatment-resistant depression, a meta-analysis of randomized, double-blind and sham-controlled study. *BMC Psychiatry*. 2014 Nov 30;14:342.
164. Loo CK, Mitchell PB, McFarquhar TF, Malhi GS, Sachdev PS. A sham-controlled trial of the efficacy and safety of twice-daily rTMS in major depression. *Psychol Med*. 2007 Mar;37(3):341-9.
165. Loo CK, Sainsbury K, Mitchell P, Hadzi-Pavlovic D, Sachdev PS. A sham-controlled trial of left and right temporal rTMS for the treatment of auditory hallucinations. *Psychol Med*. 2010 Apr;40(4):541-6.
166. Lorenz I, Müller N, Schlee W, Langguth B, Weisz N. Short-term effects of single repetitive TMS sessions on auditory evoked activity in patients with chronic tinnitus. *J Neurophysiol*. 2010 Sep;104(3):1497-505.
167. Ma SM, Ni JX, Li XY, Yang LQ, Guo YN, Tang YZ. High-Frequency Repetitive Transcranial Magnetic Stimulation Reduces Pain in Postherpetic Neuralgia. *Pain Med*. 2015 Nov;16(11):2162-70.
168. Machii K, Cohen D, Ramos-Estebanez C, Pascual-Leone A. Safety of rTMS to non-motor cortical areas in healthy participants and patients. *Clin Neurophysiol*. 2006 Feb;117(2):455-71.
169. Maiti R, Mishra BR, Hota D. Effect of High-Frequency Transcranial Magnetic Stimulation on Craving in Substance Use Disorder: A Meta-Analysis. *J Neuropsychiatry Clin Neurosci*. 2017 Spring;29(2):160-171.
170. McGirr A, Van den Eynde F, Tovar-Perdomo S, Fleck MP, Berlim MT. Effectiveness and acceptability of accelerated repetitive transcranial magnetic stimulation (rTMS) for treatment-resistant major depressive disorder: an open label trial. *J Affect Disord*. 2015 Mar 1;173:216-20.
171. McLoughlin DM, Mogg A, Eranti S, Pluck G, Purvis R, Edwards D, et al. The clinical effectiveness and cost of repetitive transcranial magnetic stimulation versus electroconvulsive therapy in severe depression: a multicentre pragmatic randomised controlled trial and economic analysis. *Health Technol Assess*. 2007 Jul;11(24):1-54.
172. McNamara B, Ray JL, Arthurs OJ, Boniface S. Transcranial magnetic stimulation for depression and other psychiatric disorders. *Psychol Med*. 2001;31(7):1141-6.
173. Mantovani A, Aly M, Dagan Y, Allart A, Lisanby SH. Randomized sham controlled trial of repetitive transcranial magnetic stimulation to the dorsolateral prefrontal cortex for the treatment of panic disorder with comorbid major depression. *J Affect Disord*. 2012b Aug 1.
174. Mantovani A, Pavlicova M, Avery D, Nahas Z, McDonald WM, Wajdik CD, et al. Long-term efficacy of repeated daily prefrontal transcranial magnetic stimulation (TMS) in treatment-resistant depression. *Depress Anxiety*. 2012a Oct;29(10):883-90.
175. Marcondes RA, Sanchez TG, Kii MA, Ono CR, Buchpiguel CA, Langguth B, et al. Repetitive transcranial magnetic stimulation improve tinnitus in normal hearing patients: a double-

blind controlled, clinical and neuroimaging outcome study. *Eur J Neurol*. 2010 Jan;17(1):38-44.

176. Marlow NM, Bonilha HS, Short EB. Efficacy of transcranial direct current stimulation and repetitive transcranial magnetic stimulation for treating fibromyalgia syndrome: a systematic review. *Pain Pract*. 2013;13(2):131-145.
177. Matheson SL, Green MJ, Loo C, Carr VJ. Quality assessment and comparison of evidence for electroconvulsive therapy and repetitive transcranial magnetic stimulation for schizophrenia: a systematic meta-review. *Schizophr Res*. 2010 May;118(1-3):201-10.
178. Mattoo B, Tanwar S, Bhatia R, Tripathi M, Bhatia R. Repetitive transcranial magnetic stimulation in chronic tension-type headache: A pilot study. *Indian J Med Res*. 2019;150(1):73-80.
179. McClelland J, Kekic M, Bozhilova N, Nestler S, Dew T, Van den Eynde F, David AS, Rubia K1, Campbell IC, Schmidt U. A Randomised Controlled Trial of Neuronavigated Repetitive Transcranial Magnetic Stimulation (rTMS) in Anorexia Nervosa. *PLoS One*. 2016 Mar 23;11(3):e0148606.
180. Minichino A, Bersani FS, Capra E, Pannese R, Bonanno C, Salviati M, et al. ECT, rTMS, and deepTMS in pharmacoresistant drug-free patients with unipolar depression: a comparative review. *Neuropsychiatr Dis Treat*. 2012;8:55-64.
181. Miniussi C, Bonato C, Bignotti S, Gazzoli A, Gennarelli M, Pasqualetti P, et al. Repetitive transcranial magnetic stimulation (rTMS) at high and low frequency: an efficacious therapy for major drug-resistant depression? *Clin Neurophysiol*. 2005 May;116(5):1062-71.
182. Mishra BR, Nizamie SH, Das B, Praharaj SK. Efficacy of repetitive transcranial magnetic stimulation in alcohol dependence: a sham-controlled study. *Addiction*. 2010 Jan;105(1):49-55.
183. Misra UK, Kalita J, Bhoi SK. High frequency repetitive transcranial magnetic stimulation (rTMS) is effective in migraine prophylaxis: an open labeled study. *Neurol Res*. 2012 Jul;34(6):547-51.
184. Mogg A, Pluck G, Eranti SV, Landau S, Purvis R, Brown RG, et al. A randomized controlled trial with 4-month follow-up of adjunctive repetitive transcranial magnetic stimulation of the left prefrontal cortex for depression. *Psychol Med*. 2008 Mar;38(3):323-33.
185. Moussavi Z, Suleiman A, Rutherford G, et al. A Pilot Randomised Double-Blind Study of the Tolerability and efficacy of repetitive Transcranial Magnetic Stimulation on Persistent Post-Concussion Syndrome. *Sci Rep*. 2019;9(1):5498. Published 2019 Apr 2.
186. Nardone R, Höller Y, Brigo F, Orioli A, Tezzon F, Schwenker K, Christova M, Golaszewski S, Trinka E. Descending motor pathways and cortical physiology after spinal cord injury assessed by transcranial magnetic stimulation: a systematic review. *Brain Res*. 2015 Sep 4;1619:139-54.
187. Naro A, Billeri L, Cannavò A, et al. Theta burst stimulation for the treatment of obsessive-compulsive disorder: a pilot study. *J Neural Transm (Vienna)*. 2019;126(12):1667-1677.

188. National Institute of Mental Health. Obsessive-compulsive disorder. 2016. Last Reviewed Jan 2025. Accessed Jan 17, 2025. Available at URL address: <https://www.nimh.nih.gov/health/topics/obsessive-compulsive-disorder-ocd/index.shtml>
189. Nguyen TD, Hieronymus F, Lorentzen R, McGirr A, Østergaard SD. The efficacy of repetitive transcranial magnetic stimulation (rTMS) for bipolar depression: A systematic review and meta-analysis. *J Affect Disord*. 2021 Jan 15;279:250-255.
190. Noh TS, Kyong JS, Park MK, et al. Treatment Outcome of Auditory and Frontal Dual-Site rTMS in Tinnitus Patients and Changes in Magnetoencephalographic Functional Connectivity after rTMS: Double-Blind Randomized Controlled Trial. *Audiol Neurotol*. 2019;24(6):293-298.
191. Nongpiur A, Sinha VK, Praharaj SK, Goyal N. Theta-patterned, frequency-modulated priming stimulation enhances low-frequency, right prefrontal cortex repetitive transcranial magnetic stimulation (rTMS) in depression: a randomized, sham-controlled study. *J Neuropsychiatry Clin Neurosci*. 2011 Summer;23(3):348-57.
192. Nordenskjöld A, Mårtensson B, Pettersson A, Heintz E, Landén M. Effects of Hesel-coil deep transcranial magnetic stimulation for depression - a systematic review. *Nord J Psychiatry*. 2016 Oct;70(7):492-7.
193. Oberman L, Edwards D, Eldaief M, Pascual-Leone A. Safety of theta burst transcranial magnetic stimulation: a systematic review of the literature. *J Clin Neurophysiol*. 2011 Feb;28(1):67-74.
194. O'Connell NE, Marston L, Spencer S, DeSouza LH, Wand BM. Non-invasive brain stimulation techniques for chronic pain. *Cochrane Database of Systematic Reviews* 2018, Issue 4. Art. No.: CD008208.
195. O'Reardon JP, Solvason HB, Janicak PG, Sampson S, Isenberg KE, Nahas Z, et al. Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial. *Biol Psychiatry*. 2007 Dec 1;62(11):1208-16.
196. Pal E, Nagy F, Aschermann Z, Balazs E, Kovacs N. The impact of left prefrontal repetitive transcranial magnetic stimulation on depression in Parkinson's disease: a randomized, double-blind, placebo-controlled study. *Mov Disord*. 2010 Oct 30;25(14):2311-7.
197. Pallanti S, Bernardi S, Di Rollo A, Antonini S, Quercioli L. Unilateral low frequency versus sequential bilateral repetitive transcranial magnetic stimulation: is simpler better for treatment of resistant depression? *Neuroscience*. 2010 May 5;167(2):323-8.
198. Pan F, Li D, Wang X, Lu S, Xu Y, Huang M. Neuronavigation-guided high-dose repetitive transcranial magnetic stimulation for the treatment of depressive adolescents with suicidal ideation: a case series. *Neuropsychiatr Dis Treat*. 2018 Oct 10;14:2675-2679.
199. Parikh TK, Strawn JR, Walkup JT, Croarkin PE. Repetitive Transcranial Magnetic Stimulation for Generalized Anxiety Disorder: A Systematic Literature Review and Meta-Analysis. *Int J Neuropsychopharmacol*. 2022 Feb 11;25(2):144-146.
200. Paykel ES. Partial remission, residual symptoms, and relapse in depression. *Dialogues Clin Neurosci*. 2008 Dec; 10(4): 431-437.

201. Pei Q, Wu B, Tang Y, et al. Repetitive Transcranial Magnetic Stimulation at Different Frequencies for Postherpetic Neuralgia: A Double-Blind, Sham-Controlled, Randomized Trial. *Pain Physician*. 2019;22(4):E303-E313.
202. Pelissolo A, Harika-Germaneau G, Rachid F, Gaudeau-Bosma C, Tanguy ML, BenAdhira R, Bouaziz N, Popa T, Wassouf I, Saba G, Januel D, Jaafari N. Repetitive Transcranial Magnetic Stimulation to Supplementary Motor Area in Refractory Obsessive-Compulsive Disorder Treatment: a Sham-Controlled Trial. *Int J Neuropsychopharmacol*. 2016 Aug 12;19(8). pii: pyw025.
203. Pereira LS, Müller VT, da Mota Gomes M, Rotenberg A, Fregni F. Safety of repetitive transcranial magnetic stimulation in patients with epilepsy: A systematic review. *Epilepsy Behav*. 2016 Apr;57(Pt A):167-76.
204. Philip NS, Barredo J, Aiken E, et al. Theta-Burst Transcranial Magnetic Stimulation for Posttraumatic Stress Disorder. *Am J Psychiatry*. 2019;176(11):939-948.
205. Philip NS, Dunner D, Dowd S, et al. Can Medication Free, Treatment-Resistant, Depressed Patients Who Initially Respond to TMS Be Maintained Off Medications? A Prospective, 12-Month Multisite Randomized Pilot Study. *Brain Stimulation*. 2016;9(2):251-7.
206. Picht T, Schmidt S, Brandt S, Frey D, Hannula H, Neuvonen T, et al. Preoperative functional mapping for rolandic brain tumor surgery: comparison of navigated transcranial magnetic stimulation to direct cortical stimulation. *Neurosurgery*. 2011 Sep;69(3):581-8; discussion 588.
207. Picht T, Schulz J, Hanna M, Schmidt S, Suess O, Vajkoczy P. Assessment of the influence of navigated transcranial magnetic stimulation on surgical planning for tumors in or near the motor cortex. *Neurosurgery*. 2012 May;70(5):1248-56; discussion 1256-7.
208. Plewnia S, Bartels M, Gerloff C. Transient suppression of tinnitus by transcranial magnetic stimulation. *Ann Neurol*. 2003 Feb;53(2):263-6.
209. PsychCentral. Remission in depression: what to know. 2018. Updated Jan 17, 2020, Apr 6, 2022. Accessed Jan 14, 2025. Available at URL address: <https://psychcentral.com/lib/severity-and-remission-in-major-depressive-episode/>
210. Quan WX, Zhu XL, Qiao H, Zhang WF, Tan SP, Zhou DF, Wang XQ. The effects of high-frequency repetitive transcranial magnetic stimulation (rTMS) on negative symptoms of schizophrenia and the follow-up study. *Neurosci Lett*. 2015 Jan 1;584:197-201.
211. Rachid F. Maintenance repetitive transcranial magnetic stimulation (rTMS) for relapse prevention in with depression: A review. *Psychiatry Res*. 2018 Apr;262:363-372.
212. Raffa G, Scibilia A, Conti A, et al. The role of navigated transcranial magnetic stimulation for surgery of motor-eloquent brain tumors: a systematic review and meta-analysis. *Clin Neurol Neurosurg*. 2019;180:7-17.
213. Rapinesi C, Bersani FS, Kotzalidis GD, Imperatori C, Del Casale A, Di Pietro S, Ferri VR, Serata D, Raccach RN, Zangen A, Angeletti G, Girardi P. Maintenance Deep Transcranial Magnetic Stimulation Sessions are Associated with Reduced Depressive Relapses in Patients with Unipolar or Bipolar Depression. *Front Neurol*. 2015 Feb 9;6:16.

214. Rapinesi C, Del Casale A, Scatena P, Kotzalidis GD, Di Pietro S, Ferri VR1, Bersani FS, Brugnoli R, Raccach RN, Zangen A, Ferracuti S, Orzi F, Girardi P, Sette G. Add-on deep Transcranial Magnetic Stimulation (dTMS) for the treatment of chronic migraine: A preliminary study. *Neurosci Lett*. 2016 Jun 3;623:7-12.
215. Rapinesi C, Kotzalidis GD, Ferracuti S, Sani G, Girardi P, Del Casale A. Brain Stimulation in Obsessive-Compulsive Disorder (OCD): A Systematic Review. *Curr Neuropharmacol*. 2019;17(8):787-807.
216. Ray S, Nizamie SH, Akhtar S, Praharaj SK, Mishra BR, Zia-ul-Haq M. Efficacy of adjunctive high frequency repetitive transcranial magnetic stimulation of left prefrontal cortex in depression: a randomized sham controlled study. *J Affect Disord*. 2011 Jan;128(1-2):153-9.
217. Rehn S, Eslick GD, Brakoulias V. A Meta-Analysis of the Effectiveness of Different Cortical Targets Used in Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Obsessive-Compulsive Disorder (OCD). *Psychiatr Q*. 2018 Sep;89(3):645-665.
218. Ren C, Zhang G, Xu X, et al. The Effect of rTMS over the Different Targets on Language Recovery in Stroke Patients with Global Aphasia: A Randomized Sham-Controlled Study. *Biomed Res Int*. 2019;2019:4589056. Published 2019 Jul 29.
219. Ren J, Li H, Palaniyappan L, Liu H, Wang J, Li C, Rossini PM. Repetitive transcranial magnetic stimulation versus electroconvulsive therapy for major depression: a systematic review and meta-analysis. *Prog Neuropsychopharmacol Biol Psychiatry*. 2014 Jun 3;51:181-9.
220. Rosa MA, Gattaz WF, Pascual-Leone A, Fregni F, Rosa MO, Rumi DO, et al. Comparison of repetitive transcranial magnetic stimulation and electroconvulsive therapy in unipolar non-psychotic refractory depression: a randomized, single-blind study. *Int J Neuropsychopharmacol*. 2006 Dec;9(6):667-76.
221. Rossi S, De Capua A, Olivelli M, Bartalini S, Falzarano V, Filippone G, et al. Effects of repetitive transcranial magnetic stimulation on chronic tinnitus: a randomised, crossover, double blind, placebo controlled study. *J Neurol Neurosurg Psychiatry*. 2007 Aug;78(8):857-63.
222. Saltychev M, Laimi K. Effectiveness of repetitive transcranial magnetic stimulation in patients with fibromyalgia: a meta-analysis. *Int J Rehabil Res*. 2017 Mar;40(1):11-18.
223. Sampson SM, Kung S, McAlpine DE, Sandroni P. The use of slow-frequency prefrontal repetitive transcranial magnetic stimulation in refractory neuropathic pain. *J ECT*. 2011 Mar;27(1):33-7.
224. Schneider SA, Pleger B, Draganski B, Cordivari C, Rothwell JC, Bhatia KP, et al. Modulatory effects of 5Hz rTMS over the primary somatosensory cortex in focal dystonia--an fMRI-TMS study. *Mov Disord*. 2010 Jan 15;25(1):76-83.
225. Schonfeldt-Lecuona C, Gron G, Walter H, Buchler N, Wunderlich A, Spitzer M et al. Stereotaxic rTMS for the treatment of auditory hallucinations in schizophrenia. *Neuro Report*. 2004 July 19; 15(10): 1669-73.

226. Schutter DJ. Antidepressant efficacy of high-frequency transcranial magnetic stimulation over the left dorsolateral prefrontal cortex in double-blind sham-controlled designs: a meta-analysis. *Psychol Med*. 2009 Jan;39(1):65-75.
227. Sehatzadeh S, Daskalakis ZJ, Yap B, et al. Unilateral and bilateral repetitive transcranial magnetic stimulation for treatment-resistant depression: a meta-analysis of randomized controlled trials over 2 decades. *J Psychiatry Neurosci*. 2019;44(3):151-163.
228. Shi R, Wang Z, Yang D, Hu Y, Zhang Z, Lan D, Su Y, Wang Y. Short-term and long-term efficacy of accelerated transcranial magnetic stimulation for depression: a systematic review and meta-analysis. *BMC Psychiatry*. 2024 Feb 7;24(1):109.
229. Shirota Y, Ohtsu H, Hamada M, Enomoto H, Ugawa Y; Research Committee on rTMS Treatment of Parkinson's Disease. Supplementary motor area stimulation for Parkinson disease: a randomized controlled study. *Neurology*. 2013 Apr 9;80(15):1400-5.
230. Sigrist C, Vöckel J, MacMaster FP, Farzan F, Croarkin PE, Galletly C, Kaess M, Bender S, Koenig J. Transcranial magnetic stimulation in the treatment of adolescent depression: a systematic review and meta-analysis of aggregated and individual-patient data from uncontrolled studies. *Eur Child Adolesc Psychiatry*. 2022 Oct;31(10):1501-1525.
231. Slotema CW, Blom JD, Hoek HW, Sommer IE. Should we expand the toolbox of psychiatric treatment methods to include Repetitive Transcranial Magnetic Stimulation (rTMS)? A meta-analysis of the efficacy of rTMS in psychiatric disorders. *J Clin Psychiatry*. 2010 Jul;71(7):873-84.
232. Slotema CW, Blom JD, de Weijer AD, Diederens KM, Goekoop R, Looijestijn J, et al. Can low-frequency repetitive transcranial magnetic stimulation really relieve medication-resistant auditory verbal hallucinations? Negative results from a large randomized controlled trial. *Biol Psychiatry*. 2011 Mar 1;69(5):450-6.
233. Sokhadze E, Baruth J, Tasman A, Mansoor M, Ramaswamy R, Sears L, et al. Low-frequency repetitive transcranial magnetic stimulation (rTMS) affects event-related potential measures of novelty processing in autism. *Appl Psychophysiol Biofeedback*. 2010 Jun;35(2):147-61.
234. Soler MD, Kumru H, Pelayo R, Vidal J, Tormos JM, Fregni F, Navarro X, Pascual-Leone A. Effectiveness of transcranial direct current stimulation and visual illusion on neuropathic pain in spinal cord injury. *Brain*. 2010 Sep;133(9):2565-77.
235. Soleimani R, Jalali MM, Hasandokht T. Therapeutic impact of repetitive transcranial magnetic stimulation (rTMS) on tinnitus: a systematic review and meta-analysis. *Eur Arch Otorhinolaryngol*. 2016 Jul;273(7):1663-75.
236. Sun CH, Mai JX, Shi ZM, Zheng W, Jiang WL, Li ZZ, Huang XB, Yang XH, Zheng W. Adjunctive repetitive transcranial magnetic stimulation for adolescents with first-episode major depressive disorder: a meta-analysis. *Front Psychiatry*. 2023 Aug 1;14:1200738.
237. Takahashi S, Vajkoczy P, Picht T. Navigated transcranial magnetic stimulation for mapping the motor cortex in patients with rolandic brain tumors. *Neurosurg Focus*. 2013 Apr;34(4):E3.
238. Takeuchi N, Tada T, Toshima M, Ikoma K. Correlation of motor function with transcallosal and intracortical inhibition after stroke. *J Rehabil Med*. 2010 Nov;42(10):962-6.

239. Tarapore PE, Tate MC, Findlay AM, Honma SM, Mizuiri D, Berger MS, Nagarajan SS. Preoperative multimodal motor mapping: a comparison of magnetoencephalography imaging, navigated transcranial magnetic stimulation, and direct cortical stimulation. *J Neurosurg*. 2012 Aug;117(2):354-62.
240. Taylor JJ, Borckardt JJ, George MS. Endogenous opioids mediate left dorsolateral prefrontal cortex rTMS-induced analgesia. *Pain*. 2012 Jun;153(6):1219-25.
241. Teepker M, Hötzel J, Timmesfeld N, Reis J, Mylius V, Haag A, et al. Low-frequency rTMS of the vertex in the prophylactic treatment of migraine. *Cephalalgia*. 2010 Feb;30(2):137-44.
242. Tendler A, Barnea Ygael N, Roth Y, Zangen A. Deep transcranial magnetic stimulation (dTMS) - beyond depression. *Expert Rev Med Devices*. 2016 Oct;13(10):987-1000.
243. Tendler A, Roth Y, Barnea-Ygael N, Zangen A. How to Use the H1 Deep Transcranial Magnetic Stimulation Coil for Conditions Other than Depression. *J Vis Exp*. 2017 Jan 23;(119).
244. Theleritis C, Sakkas P, Paparrigopoulos T, Vitoratou S, Tzavara C, Bonaccorso S, Politis A, Soldatos CR, Psarros C. Two Versus One High-Frequency Repetitive Transcranial Magnetic Stimulation Session per Day for Treatment-Resistant Depression: A Randomized Sham-Controlled Trial. *J ECT*. 2017 Sep;33(3):190-197.
245. Tor PC, Gálvez V, Goldstein J, George D, Loo CK. Pilot Study of Accelerated Low-Frequency Right-Sided Transcranial Magnetic Stimulation for Treatment-Resistant Depression. *J ECT*. 2016 Sep;32(3):180-2.
246. Torres-Castaño A, Rivero-Santana A, Perestelo-Pérez L, Duarte-Díaz A, Toledo-Chávarri A, Ramos-García V, Álvarez-Pérez Y, Cudeiro-Mazaira J, Padrón-González I, Serrano-Pérez P. Transcranial Magnetic Stimulation for the Treatment of Cocaine Addiction: A Systematic Review. *J Clin Med*. 2021 Nov 28;10(23):5595.
247. Trevizol AP, Barros MD, Silva PO, Osuch E, Cordeiro Q, Shiozawa P. Transcranial magnetic stimulation for posttraumatic stress disorder: an updated systematic review and meta-analysis. *Trends Psychiatry Psychother*. 2016 Jan-Mar;38(1):50-5.
248. Trevizol AP, Shiozawa P, Cook IA, Sato IA, Kaku CB, Guimarães FB, Sachdev P, Sarkhel S, Cordeiro Q. Transcranial Magnetic Stimulation for Obsessive-Compulsive Disorder: An Updated Systematic Review and Meta-analysis. *J ECT*. 2016 Dec;32(4):262-266.
249. Trung J, Hanganu A, Jobert S, et al. Transcranial magnetic stimulation improves cognition over time in Parkinson's disease. *Parkinsonism Relat Disord*. 2019;66:3-8.
250. Tung YC, Lai CH, Liao CD, Huang SW, Liou TH, Chen HC. Repetitive Transcranial Magnetic Stimulation of Lower Limb Motor Function in Patients With Stroke: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *Meta-Analysis Clin Rehabil*, 33 (7), 1102-1112 Jul 2019 PMID: 30864462
251. Tunkel DE, Bauer CA, Sun GH, Rosenfeld RM, Chandrasekhar SS, Cunningham ER Jr, Archer SM, Blakley BW, Carter JM, Granieri EC, Henry JA, Hollingsworth D, Khan FA, Mitchell S, Monfared A, Newman CW, Omole FS, Phillips CD, Robinson SK, Taw MB, Tyler RS, Waguespack R, Whamond EJ. Clinical practice guideline: tinnitus. *Otolaryngol Head Neck Surg*. 2014 Oct;151(2 Suppl):S1-S40.

252. U.S. Food and Drug Administration (FDA). Center for Devices and Radiological Health (CDRH). Guidance for industry and Food and Drug Administration staff. Class II special controls guidance document: repetitive transcranial magnetic stimulation (rTMS) systems. Rockville (MD); 2011 Jul 26. Content current as of Mar 23, 2018. Accessed Jan 22, 2025. Available at URL address: <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/class-ii-special-controls-guidance-document-repetitive-transcranial-magnetic-stimulation-rtms>
253. U.S. Food and Drug Administration (FDA). 510(k) Premarket Notification. Jan 20, 2025. Product code OBP, QCI, HAW, OKP. Access Jan 22, 2025. Available at URL address: <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm>
254. U.S. Food and Drug Administration (FDA). Device Classification under Section 513(f)(2)(de novo) database. Jan 22, 2025b. Product code OBP, QCI, HAW, OKP. Accessed Jan 22, 2025. Available at URL address: <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/denovo.cfm>
255. VA/DoD Clinical Practice Guideline. (2023b). Guideline for management of bipolar disorder. Accessed Jan 22, 2025. Available at URL address: <https://www.healthquality.va.gov/guidelines/MH/bd/index.asp>
256. VA/DoD Clinical Practice Guideline. (2023). Guideline for management of first-episode psychosis and schizophrenia. Accessed Jan 22, 2025. Available at URL address: <https://www.healthquality.va.gov/guidelines/MH/scz/index.asp>
257. VA/DoD Clinical Practice Guideline. (2023c). Guideline for management of headache. Accessed Jan 22, 2025. Available at URL address: <https://www.healthquality.va.gov/guidelines/Pain/headache/index.asp>
258. VA/DoD Clinical Practice Guideline. (2024). Guideline for tinnitus. Accessed Jan 21, 2025. Available at URL address: <https://www.healthquality.va.gov/guidelines/CD/tinnitus/index.asp>
259. VA/DoD Clinical Practice Guideline. (2021). The management and rehabilitation of post-acute mild traumatic brain injury. Accessed Jan 17, 2025. Available at URL address: <https://www.healthquality.va.gov/guidelines/Rehab/mtbi/index.asp>
260. VA/DoD Clinical Practice Guideline. (2022). The management of major depressive disorder. Accessed Jan 17, 2025. Available at URL address: <https://www.healthquality.va.gov/guidelines/MH/mdd/index.asp>
261. VA/DoD Clinical Practice Guideline. (2023). The management of posttraumatic stress disorder and acute stress disorder. Accessed Jan 17, 2025. Available at URL address: <https://www.healthquality.va.gov/guidelines/MH/ptsd/index.asp>
262. VA/DoD Clinical Practice Guideline. (2024). The management of stroke rehabilitation. Accessed Jan 17, 2025. Available at URL address: <https://www.healthquality.va.gov/guidelines/Rehab/stroke/index.asp>
263. Van den Eynde F, Claudino AM, Mogg A, Horrell L, Stahl D, Ribeiro W, et al. Repetitive transcranial magnetic stimulation reduces cue-induced food craving in bulimic disorders. *Biol Psychiatry*. 2010 Apr 15;67(8):793-5.

264. Wagle Shukla A, Shuster JJ, Chung JW, Vaillancourt DE, Patten C, Ostrem J, Okun MS. Repetitive Transcranial Magnetic Stimulation (rTMS) Therapy in Parkinson Disease: A Meta-Analysis. *PM R*. 2016 Apr;8(4):356-366.
265. Walter HJ, Abright AR, Bukstein OG, Diamond J, Keable H, Ripperger-Suhler J, Rockhill C. Clinical Practice Guideline for the Assessment and Treatment of Children and Adolescents With Major and Persistent Depressive Disorders. *J Am Acad Child Adolesc Psychiatry*. 2023 May;62(5):479-502.
266. Walton D, Spencer DC, Nevitt SJ, Michael BD. Transcranial magnetic stimulation for the treatment of epilepsy. *Cochrane Database of Systematic Reviews* 2021, Issue 4. Art. No.: CD011025.
267. Wang X, Mao Z, Ling Z, Yu X. Repetitive transcranial magnetic stimulation for cognitive impairment in Alzheimer's disease: a meta-analysis of randomized controlled trials. *J Neurol*. 2020;267(3):791-801.
268. Weiduschat N, Thiel A, Rubi-Fessen I, Hartmann A, Kessler J, Merl P, et al. Effects of repetitive transcranial magnetic stimulation in aphasic stroke: a randomized controlled pilot study. *Stroke*. 2011 Feb;42(2):409-15.
269. Wobrock T, Guse B, Cordes J, Wölwer W, Winterer G, Gaebel W, Langguth B, Landgrebe M, Eichhammer P, Frank E, Hajak G, Ohmann C, Verde PE, Rietschel M, Ahmed R1, Honer WG, Malchow B, Schneider-Axmann T, Falkai P, Hasan A. Left prefrontal high-frequency repetitive transcranial magnetic stimulation for the treatment of schizophrenia with predominant negative symptoms: a sham-controlled, randomized multicenter trial. *Biol Psychiatry*. 2015 Jun 1;77(11):979-88.
270. Wu SW, Maloney T, Gilbert DL, Dixon SG, Horn PS, Huddleston DA, Eaton K, Vannest J. Functional MRI-navigated repetitive transcranial magnetic stimulation over supplementary motor area in chronic tic disorders. *Brain Stimul*. 2014 Mar-Apr;7(2):212-8. doi: 10.1016/j.brs.2013.10.005.
271. Xiang H, Sun J, Tang X, Zeng K, Wu X. The effect and optimal parameters of repetitive transcranial magnetic stimulation on motor recovery in stroke patients: a systematic review and meta-analysis of randomized controlled trials. *Clin Rehabil*. 2019;33(5):847-864.
272. Xie YJ, Gao Q, He CQ, Bian R. Effect of Repetitive Transcranial Magnetic Stimulation on Gait and Freezing of Gait in Parkinson Disease: A Systematic Review and Meta-analysis. *Arch Phys Med Rehabil*. 2020;101(1):130-140.
273. Xu P, Huang Y, Wang J, An X, Zhang T, Li Y, Zhang J, Wang B. Repetitive transcranial magnetic stimulation as an alternative therapy for stroke with spasticity: a systematic review and meta-analysis. *J Neurol*. 2021 Nov;268(11):4013-4022.
274. Yan T, Xie Q, Zheng Z, Zou K, Wang L. Different frequency repetitive transcranial magnetic stimulation (rTMS) for posttraumatic stress disorder (PTSD): A systematic review and meta-analysis. *J Psychiatr Res*. 2017 Jun;89:125-135.
275. Zhang JJQ, Fong KNK, Ouyang RG, Siu AMH, Kranz GS. Effects of repetitive transcranial magnetic stimulation (rTMS) on craving and substance consumption in patients with substance dependence: a systematic review and meta-analysis. *Addiction*. 2019;114(12):2137-2149.

276. Zhang L, Xing G, Shuai S, Guo Z, Chen H, McClure MA, Chen X, Mu Q. Low-Frequency Repetitive Transcranial Magnetic Stimulation for Stroke-Induced Upper Limb Motor Deficit: A Meta-Analysis. *Neural Plast.* 2017;2017:2758097.
277. Zhang YQ, Zhu D, Zhou XY, Liu YY, Qin B, Ren GP, Xie P. Bilateral repetitive transcranial magnetic stimulation for treatment-resistant depression: a systematic review and meta-analysis of randomized controlled trials. *Braz J Med Biol Res.* 2015 Mar;48(3):198-206.
278. Zheng CJ, Liao WJ, Xia WG. Effect of combined low-frequency repetitive transcranial magnetic stimulation and virtual reality training on upper limb function in subacute stroke: a double-blind randomized controlled trial. *J Huazhong Univ Sci Technolog Med Sci.* 2015 Apr;35(2):248-54.
279. Zhong L, Wen X, Liu Z, Li F, Ma X, Liu H, Chen H. Effects of bilateral cerebellar repetitive transcranial magnetic stimulation in poststroke dysphagia: A randomized sham-controlled trial. *NeuroRehabilitation.* 2023;52(2):227-234.
280. Zhou DD, Wang W, Wang GM, Li DQ, Kuang L. An updated meta-analysis: Short-term therapeutic effects of repeated transcranial magnetic stimulation in treating obsessive-compulsive disorder. *J Affect Disord.* 2017 Jun;215:187-196.

Revision Details

Type of Revision	Summary of Changes	Date
Annual Review	Revised the policy statement for TMS for MDD. Revised the policy statements for repeat TMS for MDD and OCD.	3/15/2024
Focused Review	No clinical policy statement changes.	11/15/2024
Annual Review	No clinical policy statement changes.	3/15/2024

All Evernorth Health Services products and services are provided exclusively by or through affiliates of the Evernorth companies. © 2025 Evernorth Health Services